Review

Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases

Giulia Gentile 1, Giovanna Morello 1, Valentina La Cognata 1, Maria Guarnaccia 1, Francesca Luisa Conforti 2* and Sebastiano Cavallaro 1,*

1 Institute for Biomedical Research and Innovation, Department of Biomedical Sciences, National Research Council (CNR), Via Paolo Gaifami, 18, 95126 Catania, Italy; giulia.gentile@cnr.it (G.G.); giovanna.morello@irib.cnr.it (G.M.); valentina.lacognata@irib.cnr.it (V.L.C.); maria.guarnaccia@cnr.it (M.G.)
2 Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via Pietro Bucci, Arcavacata, 87036 Rende, Italy; francescaluisa.conforti@unical.it
* Correspondence: sebastiano.cavallaro@cnr.it

Abstract: Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are representative neurodegenerative diseases (NDs) characterized by degeneration of selective neurons, as well as the lack of effective biomarkers and therapeutic treatments. In the last decade, microRNAs (miRNAs) have gained considerable interest in diagnostics and therapy of NDs, owing to their aberrant expression and their ability to target multiple molecules and pathways. Here, we provide an overview of dysregulated miRNAs in fluids (blood or cerebrospinal fluid) and nervous tissue of AD, PD, and ALS patients. By emphasizing those that are commonly dysregulated in these NDs, we highlight their potential role as biomarkers or therapeutical targets and describe the use of antisense oligonucleotides as miRNA therapies.

Keywords: post-mortem human tissues; iPSC-derived neurons; circulating fluids; AD; PD; ALS; ASOs-based therapies; drug biomarkers; miR-124; miR-218

1. Introduction

Neurodegenerative diseases (NDs) selectively affect distinct brain regions and neuronal types with different molecular processes and the aggregation of misfolded proteins [1]. This is the case of Alzheimer’s disease (AD) [2], Parkinson’s disease (PD) [3], and Amyotrophic Lateral Sclerosis (ALS) [4].

AD represents the most common ND of aging and the leading cause of dementia worldwide and is characterized by the accumulation of amyloid-β (Aβ) and tau aggregates in different brain areas [2,5]. PD is the most common neurodegenerative movement disorder and is characterized by the loss of dopaminergic neurons (DNs) in substantia nigra pars compacta (SNpc) and the accumulation of toxic amyloid structures made up of α-synuclein aggregates [3,6]. ALS, also known as Lou Gehrig’s disease, represents a progressive neurodegenerative disease of adulthood and is due to the progressive degeneration of upper and/or lower motor neurons (MNs) and, in some cases, by ubiquitinated protein aggregates [4,7]. Even if some treatments are able to alleviate symptoms or prolong life expectancy, there is still no cure for these NDs [8–13] and the primary goal today is the identification of effective therapies. The development of new treatment options requires a better understanding of the molecular basis underlying these pathological conditions and the identification of sensitive and specific disease biomarkers to aid early diagnosis and monitor disease progression and response to treatment.

Different non-coding RNAs have been proposed as biomarkers of neurodegeneration and, among them, microRNAs (miRNAs) have attracted the scientific community’s attention thanks to their role as key regulators of gene expression [14–17]. MiRNAs are short molecules (20–22 nucleotides) able to degrade or inhibit the translation of their multiple
complementary mRNA targets in a cell- and tissue-specific manner [17]. Common target sites for endogenous miRNAs are located in the 3′ UTR region of mRNAs where they form an imperfect duplex hybrid and regulate their translation [18]. Their role in the nervous system is not limited to cells where they are produced, but numerous extracellular miRNAs are released and exchanged in a cross-talk between blood, cerebrospinal fluids (CSF), brain, and periphery [19].

Several miRNAs were found dysregulated in human pathology and animal models of NDs, supporting their role as disease biomarkers. More recently, the molecular and functional overlapping of dysregulated miRNAs has been reported in different NDs [15]. Due to their increasing importance in pathology, miRNA-based therapeutic strategies are also gaining interest. Indeed, miRNA suppression or replacement by antisense oligonucleotides (ASOs) technologies can be successfully used in animal models or in patients with NDs [9–11,13,20].

While fluids, such as plasma, serum, or CSF offer the possibility to monitor drug effects by the expression of biomarkers during the onset/progression of NDs, changes observed in nervous tissues are fundamental to define their direct or indirect implication in neurodegeneration [21]. The analysis of miRNAs in both fluids and nervous tissues may help to characterize their dynamic inter-communication between periphery (blood and organs) and brain (blood and brain, blood and CSF, CSF and brain) [19] and prioritize their selection as disease biomarkers and therapeutical targets.

To better investigate the role of miRNAs or their targets in the pathogenesis of NDs and evaluate their potential application as biomarkers, here we review miRNAs that were found dysregulated (in at least two independent studies) in post-mortem nervous tissue, as well as fluids of patients affected by AD, PD, and ALS. By emphasizing those that are commonly dysregulated in these NDs, we highlight their potential role as biomarkers or therapeutical targets and describe the use of antisense oligonucleotides as miRNA therapies.

2. AD

AD represents the most common age-related neurodegenerative disorder and is characterized by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles (NFTs) in different brain districts. The majority of cases manifest as a late-onset sporadic form (sAD), whereas familial forms (fAD) are mainly due to pathogenic variants in APP, PSEN1, and PSEN2 [22]. From a molecular perspective, AD is characterized by extracellular deposits of Aβ peptides, generated in the amyloidogenic pathway from the cleavage of APP by BACE1 and γ-secretase, and by the intracellular accumulation of strings of hyperphosphorylated Tau proteins known as neurofibrillary tangles (NFTs) [23]. In particular, Aβ peptides accumulation is due to the unbalanced synthesis and clearance of Aβ oligomers, and the mechanisms involved in Aβ clearance include ubiquitin–proteasome system (UPS), autophagic processes, proteolytic regulation and clearance of blood-brain barrier (BBB) [24].

As shown in Table 1, 17 miRNAs (miR-7, miR-9, miR-16, miR-29a, miR-29b, miR-32, miR-34a, miR-34c, miR-101, miR-124, miR-125b, miR-128, miR-132, miR-135a, miR-146a, miR-195, and miR-218) were found dysregulated by at least two independent studies in different brain regions and fluids of AD patients. Four of them (miR-9, miR-124, miR-125b, and miR-195) were also implicated in AD iPSC-derived neurons (Table 1).
| miRNAs | AD post-mortem CNS/AD iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|--------|-------------------------------------------|------------------|-------------------|--------------------|
| miR-7  | Up-regulated in hippocampus [25,26], entorhinal cortex, middle temporal gyrus, posterior cingulate cortex, superior frontal gyrus [26], and cortex [27]; down-regulated in grey matter [28], anterior cingulate gyrus (Brodmann area 24), motor cortex [29], and temporal cortex [30] | UCHL1 [31]; UBE2A [32] | Ubiquitin-mediated clearance of amyloid peptides mediated by ciRS-7 [32]; NF-κB-dependent regulation of APP and BACE1 protein and degradation by proteasome and lysosome through UCHL1 [31]; insulin signaling through HNRNPK-miR-7 axis [27] | Detected in peripheral blood [33] |
| miR-9  | Down-regulated in the anterior temporal cortex [34], grey matter [28], cerebellum, hippocampus, medial frontal gyrus [25], and temporal cortex [30]; up-regulated in hippocampal CA1 region [35], and temporal lobe neocortex (Brodmann area A22) [36]; used to obtain a rapid neuronal differentiation and an AD disease phenotypes detected at early time points due to rapid maturation of iPSCs [37] | BACE1 [34]; CREB [38]; OPTN [39]; CAMKK2 [40]; TGFBI, TRIM2, SIRT1 [41] | miR-9 mediates the expression of BACE1 by directly regulating CREB [38]; autophagy [39]; CAMKK2-AMPK2 pathway [40] | Down-regulated in whole blood of LOAD patients [42]; CSF decreasing with increasing of Braak stages [43]; up-regulated in exosome enriched CSF [44] |
| miR-16 | Down-regulated in white matter [28], and Braak VI hippocampus [45]; up-regulated in Braak III/IV | APP [46]; TAU1 [47] | | Decreasing with the increasing of Braak stages in serum [43]; down-regulated in CSF [48] |
| miR-29a | Down-regulated in the anterior temporal cortex [34], medial frontal gyrus [25], and grey matter [28] | BACE1 [34] | BACE1/β-secretase expression [34] | Up-regulated in CSF [49], and cell-free CSF [50]; down-regulated in CSF [48] |
| miR-29b | Down-regulated in anterior temporal cortex [34], parietal lobe cortex [51], grey matter [28], dorsolateral prefrontal cortex (Brodmann area 9) and temporal cortex (Brodmann area 21/22) [52]; up-regulated in medial frontal gyrus [25] | BACE1 [34] | BACE1/β-secretase expression [34] | Up-regulated in CSF [49] |
| miR-32 | Down-regulated in the cerebellum, hippocampus, medial frontal gyrus [25], and white matter [28] | MECP2 [53] | Feedback loop with MeCP2 and BDNF for homeostatic regulation of MeCP2 [53] | Up-regulated in CSF [25], and in serum [30] |
| miR-34a | Up-regulated in cerebellum, hippocampus, medial frontal gyrus [25], hippocampal CA1 [34], anterior cingulate gyrus (Brodmann area 24) and motor cortex [29]; down-regulated in grey matter [28] | TREM2 [54]; SHANK3 [55] | Synaptogenesis and phagocytosis [54,55] | Down-regulated in plasma and CSF [49] |
| miR-34c | Down-regulated in white matter [28]; up-regulated in the hippocampus [56], Braak stage III/IV hippocampus [45], anterior cingulate gyrus (Brodmann area 24), and motor cortex [29] | SIRT1 [56] | | Up-regulated in serum [43] |
Table 1. Cont.

| miRNAs | AD post-mortem CNS/AD iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|--------|------------------------------------------|------------------|-------------------|-------------------|
| miR-101 | Down-regulated in white matter [28], anterior temporal cortex [34], and parietal lobe cortex [51] | APP [57] | IL-1β-induced APP up-regulation [57] | Down-regulated in CSF [43] |
| miR-124 | Down-regulated in gray matter [28], frontal cortex [58], temporal cortex [30]; up-regulated in iPSC-derived iNEU-PSEN hippocampal neuron from the AD patient [59] | BACE1 [58,60]; PTPN1 [61,62]; APP [59] | PTPN1 signaling [61] | Down-regulated in CSF [43] |
| miR-125b | Up-regulated in hippocampal CA1 region [35,54], temporal lobe neocortex (Brodmann area A22) [36], cerebellum, hippocampus, medial frontal gyrus [25], frontal cortex (Brodmann areas 6 and 8) [63], iPSC-derived iNEU-PSEN hippocampal neuron from the AD patient [59], and APP and PS1 variants of hippocampal spheroids differentiated from iPSC (3D hippocampal structures) [64]; down-regulated in grey matter [28] | CFH [65]; DUSP6, PPP1CA; BCLW [63]; CDKN2A [66]; NR2A [67] | CFH-driven pathogenic signaling [65]; miR-125b-induced tau hyperphosphorylation [65]; astroglisis and glial cell proliferation [66]; FMRP-associated up-regulated miRNA induces long narrow spines [67] | Down-regulated in CSF [48,49]; up-regulated in CSF [68] |
| miR-128 | Up-regulated in hippocampal CA1 [35,55], Braak III/IV and decreased in Braak VI hippocampus [45], and temporal cortex [30]; down-regulated in cerebral cortical gray matter [28], and hippocampus of LOAD patients [69] | PPARG via regulation of the NF-κB pathway [70] | NF-κB pathway [70] | Up-regulated in monocytes and lymphocytes from AD patients [71] |
| miR-132 | Up-regulated in hippocampal CA1 region [35,55], anterior cingulate gyrus (Brodmann area24) and motor cortex [29]; down-regulated in cerebellum, medial frontal gyrus [25], temporal cortex [30,72], frontal cortex [72], prefrontal cortex [73], olfactory bulb [74], hippocampus [25,72–74], and hippocampus and prefrontal cortex of LOAD [69] | P250GAP [75]; PTBP2 [76]; HDAC3 [77]; tau levels [72]; ITPKB [73]; SIRT1 [74]; HNRNPU [78] | FMRP-associated up-regulated miRNA increases dendritic protrusion width [67]; miR-132/ITPKB pathway [73]; CREB-regulated miRNA regulates neuronal morphogenesis [75]; HDAC3 signaling pathway [77]; hippocampal pro-neurogenic signal rescue [79] | Down-regulated in CSF [43]; up-regulated in plasma [80] |
| miR-135a | Up-regulated in hippocampus [25], anterior cingulate gyrus and motor cortex [29]; down-regulated in gray matter [28], and frontal cortex [61] | BACE1 [82]; THBS1 [83] | CEβP/ miR135a/THBS1 axis promotes angiogenesis [83]; Rock2/Add1 signaling pathway-miRNA regulated mediates the synaptic/memory impairments [81] | Up-regulated in CSF [25], serum [43], and exosomal serum [84] |
| miRNAs | AD post-mortem CNS/AD iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|--------|------------------------------------------|-----------------|-------------------|--------------------|
| miR-146a | Up-regulated in hippocampal [85,86] and superior temporal lobe neocortex [36,85,86], hippocampal CA1 [54,55], Braak III/IV and decreased in Braak VI hippocampus [45]; down-regulated in temporal cortex [30] | CFH [65,85], IRAK-1 and IRAK-2 [86,87], SHANK3 [55], Srsf6 [88] | Altered innate immune response and neuroinflammation through CFH modulation [65,85]; TLR/IL-1R-IRAK-NF-κB signaling causing altered innate immune response and inflammatory gene expression [86] | Down-regulated in plasma [49], CSF [45,48,49], and serum [30,89] |
| miR-195 | Down-regulated in gray matter [28], hippocampus [90], iPSC-derived astrocytes from ApoE4+/+ AD subjects compared to ApoE3+/+ normal aging iPSC-derived astrocytes [90] | BACE1 [91]; APP and BACE1 [92] | ApoE-synj1-PIP2 pathway [90] | Down-regulated in CSF [25,48,90]; up-regulated in plasma [80] |
| miR-218 | Down-regulated in gray matter [28], and temporal cortex [30]; up-regulated in dorsolateral prefrontal cortex (Brodmann area 9) and temporal cortex (Brodmann area 21/22) [52] | PTPα [93]; C3 [94] | ER-regulated tau phosphorylation [93] | Up-regulated in blood [95] |
These miRNAs may regulate key genes and signaling pathways involved in the amyloidogenic pathway, Aβ clearance, tau hyperphosphorylation, and aggregation (Table 1). The transcription factor NF-κB is known to regulate multiple pathways through its different targets, among which are APP and BACE1 [96], as well as several miRNAs (miR-7, miR-34a, miR-125b, miR-128, and miR-146a) listed in Table 1. The amyloidogenic pathway can be affected through down-regulation of BACE1 by miR-9, miR-29a, miR-29b, miR-124, miR-135a, and miR-195, or Aβ clearance impairment by miR-7, miR-9, miR-16, miR-34a and miR-101. Dysregulation of miR-16, miR-124, miR-125b, miR-132, and miR-218 affects tau protein levels and/or phosphorylation, and four of them (miR-16, miR-124, miR-125b, and miR-132) are known to deregulate either amyloid β or tau pathways by acting on different targets.

The following AD-specific miRNAs were reported as potential diagnostic biomarkers in circulating fluids: miR-16 [48], miR-29a [48–50], miR-29b [49], miR-32 [25], miR-34a [49], miR-34c [43], miR-101 [43], miR-125b [48,49,68], miR-128 [71], miR-135a [25,84], and miR-195 [25,48]. Among these, miR-16 [43] and miR-195 [90] were proposed as biomarkers of disease progression.

Dysregulation of microRNAs may profoundly influence AD-related pathways. To interpret the functions of dysregulated miRNAs in AD, we investigated the over-represented gene ontologies (GO), annotated in miRTarBase and enriched with the 17 AD dysregulated miRNAs using the miRNA Enrichment Analysis and Annotation Tool (miEAA) (Table S1) [97]. In addition to the typical mechanisms related to AD neuropathology, GOs related to glucose dysregulation, inflammation, and immune response were also enriched [98,99]. Indeed, the list of over-represented GO with the highest numbers of occurrences included: the apoptotic process (GO0006915, q-value 0.0025003), insulin receptor signaling pathway (GO0008286, q-value $6.21 \times 10^{-6}$), immune response (GO0006955, q-value 0.0023718), cellular response to oxidative stress (GO0034599, q-value $1.48 \times 10^{-4}$), negative regulation of intrinsic apoptotic signaling pathway (GO2001243, q-value $4.79 \times 10^{-8}$), positive regulation of intrinsic apoptotic signaling pathway (GO2001244, q-value $4.86 \times 10^{-7}$), positive regulation of autophagy (GO0010508, q-value $2.55 \times 10^{-5}$), response to cytokine (GO0034097, q-value $2.71 \times 10^{-5}$), glucose homeostasis (GO0042593, q-value $7.17 \times 10^{-4}$) and inflammatory response (GO0006954, q-value 0.0151675).

3. PD

PD is a severely debilitating neurodegenerative disease associated with motor symptoms such as slowness of movement, stiffness, tremor, and postural instability [100,101]. It is characterized by the accumulation of α-synuclein in neuronal perikarya (Lewy bodies) and neuronal processes (Lewy neurites), and the selective loss of DNs in substantia nigra, which results in striatal dopaminergic deficiency [101]. Current treatments aimed at preserving DNs or compensating dopamine deficit (such as levodopa and deep brain stimulation) can relieve motor symptoms but are not effective in halting or slowing disease progression [100,101].

Although the molecular mechanisms underlying PD are not fully elucidated, the progressive deterioration of vulnerable DNs arises from several cellular disturbances, including protein misfolding and aggregation, synaptic damages, apoptosis, mitochondrial dysfunctions, oxidative stress, impairment of the UPS, and neuroinflammation [102].

Multiple genetic and environmental causes of PD have been described and clarified in the last decades. Approximately 5–10% of all patients suffer from a monogenic form of PD caused by mutations in autosomal-dominant (AD)—SNCA, LRRK2, and VPS35—or autosomal recessive (AR)—PINK1, DJ-1, and PARK2—genes [103,104]. The majority of PD cases are sporadic and result from a combination of common genetic risk loci in concert with environmental factors (lifestyle, exposure to toxins, physical activity) [101].

Dysregulation of miRNA expression profiles has been described in several brain areas and fluids of PD patients, as well as in iPSCs-derived DNs generated from affected patients. Table 2 shows a list of 15 miRNAs (let-7b, miR-34b, miR-124, miR-126, miR-132,
miR-133b, miR-144, miR-148b, miR-184, miR-199a, miR-204, miR-218, miR-221, miR-338, miR-425) that were found dysregulated by at least two independent studies in nervous tissues (midbrain, prefrontal cortex, amygdala, laser-micro dissected DNAs, or anterior cingulate gyrus) [105–118], iPSC-derived DNAs [119] and circulating fluids (CSF, plasma, serum, peripheral blood) [119–148] of PD patients, thus supporting their potential utility as biomarkers and/or therapeutic targets.

Three dysregulated miRNAs (miR-34b, miR-218, miR-221) interact with PD-related genes (DJ1, PRKN, SNCA) and modulate their functions in different PD cellular and animal models, while others (miR-133b, miR-126, miR-132, miR-144, miR-425 and miR-124) participate in neuronal apoptosis and survival signaling pathways, as well as in autophagy mechanisms (Table 2).

The following PD-specific miRNAs have been reported as potential diagnostic biomarkers in circulating fluids: miR-126 [122], miR-144 [124], miR-184 [145], miR-204 [127] and miR-221 [120,128–130]. Among them, miR-144 has been proposed as an early biomarker [123]. Let-7b [144] and miR-148b [146] were proposed as biomarkers for differential diagnosis of PD from multiple system atrophy, while miR-204 [126] and miR-425 [132] from PSP. Lastly, miR-199a was proposed for the stage-specific diagnosis of PD [133].

To interpret the functions of dysregulated miRNAs in PD, we investigated the over-represented GO, annotated in miRTarBase and enriched with the 15 PD dysregulated miRNAs using miEAA (Table S2) [97]. Many of the categories are implicated in PD pathogenesis and include neuroinflammatory/immune responses (positive regulation of prostaglandin biosynthetic process GO0031394, q-value $1.36 \times 10^{-6}$; regulation of neuroinflammatory response GO0150077, q-value $3.22 \times 10^{-4}$; macrophage cytokine production GO0010934, q-value $3.22 \times 10^{-4}$), cell death and apoptosis (negative regulation of hydrogen peroxide-mediated programmed cell death GO1901299, q-value $2.54 \times 10^{-5}$; positive regulation of intrinsic apoptotic signaling pathway GO2001244, q-value $4.94 \times 10^{-4}$), and neurodevelopment (tube formation GO0035148, q-value $1.54 \times 10^{-4}$; nerve development GO0021675 q-value $2.34 \times 10^{-4}$; branching morphogenesis of an epithelial tube GO0048754, q-value $3.22 \times 10^{-4}$).
Table 2. Dysregulated miRNAs in human PD post-mortem tissues and circulating fluids.

| miRNAs | PD post-mortem CNS/ PD iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|--------|---------------------------------------------|------------------|-------------------|-------------------|
| let-7b | Up-regulated in DA neurons [113], and PD-specific iPSC-derived midbrain neurons [115]; down-regulated in amygdala [114] | HMGA2 [149]  | | Discriminating multiple system atrophy (an atypical parkinsonian disorder) from control [144] |
| miR-34b | Down-regulated in putamen [150], FC, amygdala, SN, and cerebellum [115] | ADORA2A [150];DJ1 and Parkin [151]; α-synuclein [152] | Apoptosis and Autophagy [154]; AMPK/mTOR pathway [162]; MALAT1/miR-124-3p/DAPK1 signaling cascade mediating apoptosis [163]; Calpain/cdk5 pathway [164]; Hedgehog Signaling Pathway/EDN2 [157]; STT1/NF-κB axis [165]; miR-124-3p/KLF4 axis [166]; miR-124-3p/PTEN/AKT/mTOR pathway [167] | Up-regulated in serum of multiple system atrophy patients vs PD for differential diagnosis [146]; detected in CSF [140] |
| miR-124 | Down-regulated in prefrontal cortex of the left cerebral hemisphere [107]; up-regulated in amygdala [114] | KPNB1, KPNA3, KPNA4 [107]; p53/p21 [153]; Bim [154]; C1q3 [155]; ANXA5 [156]; EDN2 [157]; MEK3 [158]; STAT3 [159]; NEAT1/PDE4B [160]; NEAT1 [161] | | Reduced plasma levels in PD [136]; down-regulated in plasma [137]; up-regulated in plasma [136] |
| miR-126 | Up-regulated in DA neurons [112,113], and amygdala [114] | SP1 [168]; PLK2 [169]; LncRNA HOTAIR/RAB3IP [170]; IRS-1/PDK3R2 [171] | Insulin/IGF-1/P21KK signaling pathway [112]; GF/P3K/AKT and ERK signaling cascades [171] | Down-regulated in CSF exosome [143], and blood [121,122] |
| miR-132 | Down-regulated in prefrontal cortex (Brodmann Area 9) [116], and in meta-analysis from different PD brain specimens [172]; up-regulated in midbrain [117] | ncRNA MIAT [173]; ULK1 [174]; Nurr1 [175]; GLRX [117] | SIRT1/P53 pathway [176] | Up-regulated in peripheral blood [147,148], and exosomes isolated from CSF [143]; down-regulated in serum samples [125] |
| miR-133b | Down-regulated in midbrain [105,106,172] | Pitx3 [105]; FAIM [177]; RhoA [176]; SNHG14 [179]; Gdf5 [180] | Inhibition of cell apoptosis by regulating the ERK1/2 signaling pathway [181]; Xist/miR-133b-3p/Pitx3 axis [182] | Up-regulated in plasma [120]; down-regulated in plasma [131], and serum [142] |
| miR-144 | Up-regulated in the prefrontal cortex (Brodmann Area 9) [116], and anterior cingulate gyrus [118]; down-regulated in the prefrontal cortex of the left cerebral hemisphere [107] | KPNB1, KPNA3, and KPNA4 [107]; β-amyloid precursor protein [183] | NF-κB signaling pathway [107] | Down-regulated in serum [123]; up-regulated in CSF [124] |
| miR-148b | Down-regulated in the prefrontal cortex (Brodmann Area 9) [116], and amygdala [114] | | | Down-regulated in blood [146] |
| miR-184 | Up-regulated in DA neurons [113] and amygdala [114] | Up-regulated in exosomes; down-regulated in plasma [145] | | |
Table 2. Cont.

| miRNAs  | PD post-mortem CNS/PD iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|---------|-------------------------------------------|------------------|------------------|--------------------|
| miR-199a | Up-regulated in the amygdala [114]; down-regulated in iPSC-derived DNs from PD patients [119] |  |  | Stage-specific biomarker in serum extracellular vesicles [133] |
| miR-204 | Up-regulated in putamen [108]; down-regulated in amygdala [114] | SLC5A3 [184]; DYRK1A [185] |  | Up-regulated in CFS of Progressive Supranuclear Palsy (PSP) patients [126]; differentially expressed in plasma samples [127]; detected in CSF of patients with parkinsonian syndromes [144] |
| miR-218 | Up-regulated in the amygdala [114], and midbrain [110]; down-regulated in the prefrontal cortex of the left cerebral hemisphere [107] | RA86C [110,186]; LASP1 [187]; KPNB1, KPNA3, KPNA4 [107]; PRKN [188] | NF-κB signaling pathway [107] | Down-regulated after 1 h of deep brain stimulation [134,135]; up-regulated in plasma [145] |
| miR-221 | Up-regulated in putamen [108], anterior cingulate gyrus [118], and amygdala [114] | LncRNA MIAT [189]; LncRNA HOTAIR [190]; LncRNA SNHG1 [191]; DJ1 [192]; TFR2 [193]; FMR1 [194] | TGF-β1/Nrf2 axis [189]; miR-221/222/p27/mTOR pathway [191] | Up-regulated in plasma [120]; down-regulated in serum [128–130] |
| miR-338 | Down-regulated in prefrontal cortex (Brodmann Area 9) [116], and amygdala [114] | SPI1 [195] |  | Decreased levels in plasma extracellular vesicles [139] |
| miR-425 | Up-regulated in putamen [108]; down-regulated in SN [109] | RIPK1 [109] | miR-425-5p/TRAF5/NF-κB axis [196] | Able to discriminate PD from PSP [132] |
4. ALS

ALS is a progressive neurodegenerative disease characterized by selective degeneration of upper and lower MNs, resulting in muscle weakness and atrophy, with respiratory failure and ultimately death 3–5 years after the first clinical manifestation [197]. Only a fraction of ALS cases (approximately 10%) is familiar (fALS), because of mutations in genes involved in a wide range of cellular functions, whereas the vast majority of ALS cases are sporadic (sALS) [197]. Rilutek (riluzole) and Radicava (edaravone) are the only two drugs approved for ALS, which only slightly slow disease progression [198].

Understanding the etiopathogenesis of ALS is crucial for the implementation of effective therapies that are urgently needed. ALS is considered to have a complex etiology involving multiple genes and environmental factors. Among the implicated pathological processes are protein aggregation, glutamate excitotoxicity, defects in stress response, mitochondrial dysfunction, protein aggregation, altered axonal transport, and aberrant RNA metabolism [199–201]. The role of this last, in particular, seems particularly central when considering that several ALS-linked genes, such as TARDBP or FUS, are key components of coding and noncoding RNA processing machinery [17,202–208].

The role of miRNAs in ALS pathology is highlighted by several studies describing dysregulated miRNAs in the spinal cord, brain, blood, CSF, and iPSCs of ALS patients [209–215]. Here we focused our attention on a list of 9 miRNAs (miR-9, miR-124, miR-142, miR-146a, miR-155, miR-218, miR-133a, miR-133b, miR-338), which were found differentially expressed in both tissues (cortex and spinal cord) and fluids of ALS patients. Four of these (miR-9, miR-218, miR-133a, and miR-133b) were also implicated in iPSC-derived MNs of ALS patients, further supporting their potential utility as biomarkers and/or therapeutical targets (Table 3).
| miRNAs | ALS post-mortem CNS/ALS iPSC-Derived Neurons | Validated Target | Signaling Pathway | Circulating Fluids |
|--------|---------------------------------------------|------------------|------------------|-------------------|
| miR-9  | Down-regulated in lumbar motor neurons [202,215,216]; dysregulated in ALS-specific iPSC-derived MN lines [217,218] | NEFL [215,216]; PRPH [218]; FoxP1 [219]; PAK4 [220] | Neuronal transcription programs, neurofilaments aggregate formation [215,216,221] | Increased in peripheral leukocytes from ALS patients [222] |
| miR-124| Down-regulated in spinal cord [202,214] | Sox2, Sox9 [223] | Immune responses, neuroinflammation, neuronal development, synaptic plasticity, neurodegeneration [222-226] | Dysregulated in the CSF and leukocytes of ALS patients [222,227,228] |
| miR-133a/b | Down-regulated in spinal cord tissue [212,229], and ALS-specific iPSC-derived MN [210] | FAS, CD4, EIF2C4/AGO4, CCL2, and AQP1 [212] | Cell death, defense response, immune response, and inflammation [212] | Up-regulated in serum [230,231] |
| miR-142| Up-regulated in spinal cord tissue [212,229] | CAMK2A [232]; Vimentin [233]; IL-6 [234]; CDKN1B, TIMP3 [235]; NRF2 [237] | Cell death, defense responses, immune responses and inflammation [212,238] | Dysregulated in CSF of ALS patients [227,238-240] |
| miR-146a| Dysregulated in spinal cord tissue [215,216,229] | NEFL [215,216] | Neurofilaments aggregate formation [215,216]; neuroinflammation [241] | Up-regulated in blood plasma from ALS/MND patients [242] |
| miR-155| Up-regulated in spinal cord [212,214,229] | SHIP1 [229]; SOCS1 [243]; SMAD2 [244]; SMAD5 [245]; TGF-β [246] | Cell death, defense responses, immune responses and inflammation [212] | Increased in peripheral monocytes from ALS patients [247] |
| miR-218| Down-regulated in spinal cord tissue [212,229]; up-regulated in ALS-specific iPSC-derived MN [248] | Kcnh1 [249]; SLC1A1, SLC1A2 [248]; Tad1, SLC6A1, BCL11A, Lhx1 and FoxP2 [250] | Development, membrane excitability, NMJ synaptic connections [249] | Down-regulated in peripheral blood, CSF, serum and neuromuscular junction of ALS patients [251] |
| miR-338| Up-regulated in spinal cord tissue [252], and motor cortex samples [209,212] | ATP5G1 [253] | Apoptosis, oligodendrocyte differentiation, maturation, mitochondrial function [254] | Up-regulated in peripheral blood, CSF, serum and neuromuscular junction of ALS patients [222,251,252,254,255] |
Most ALS-related miRNAs mentioned above regulate the expression of genes involved in oxidative stress and neuroinflammation, whereas two of them (miR-155 and miR-142) are predicted regulators of ALS-related gene transcripts (TARDBP, UBQLN2, KIF5A, and C9orf72). In particular, miR-155 promotes tissue inflammation and macrophage inflammatory responses by targeting several immune response-related gene transcripts, including SOCS1, C/EBPβ, TGF-β, SMAD2, and SMAD5 [243–245,256,257]. Increased levels of miR-155 were found both in spinal cord tissue and peripheral monocytes of ALS patients and its inhibition increases survival time and disease duration in a murine ALS model, supporting the possibility to use this miRNA as a therapeutical target [212,214,229,247] (Table 3).

MiR-142 is an important regulator of neuronal viability and apoptosis. Its inhibition produces neuroprotective effects by reducing neuronal injury and oxidative stress via the IL-6 and Nrf2/ARE signaling pathways and modulates axonal transport and mitochondrial activity in MNs by targeting vimentin and other intermediate filament types [232–235,258,259].

Functional enrichment analysis of the 9 dysregulated miRNAs in post-mortem tissues and circulating fluids of ALS patients produces a list of over-represented GO terms, many of which were previously implicated in ALS pathogenesis (Table S3) [97]. Among these are multiple processes involved in neuroinflammatory/immune responses, such as epidermal growth factor receptor signaling activity (GO0005006, q-value 1.07 × 10^{-6}), regulation of neuroinflammatory response (GO0150077, q-value 2.74 × 10^{-6}), activation of phospholipase A2 activity by calcium-mediated signaling (GO0043006, q-value 3.42 × 10^{-6}), positive regulation of interleukin-17 biosynthetic process (GO0045380, q-value 3.42 × 10^{-6}), regulation of astrocyte activation (GO0061888, q-value 3.42 × 10^{-6}), NAD-dependent histone deacetylase activity (GO0017136, q-value 1.34 × 10^{-5}), negative regulation of ERBB signaling pathway (GO1901185, q-value 1.13 × 10^{-5}), positive regulation of cytokine activity (GO0060301, q-value 1.44 × 10^{-5}), C-X-C motif chemokine 12 receptor activity (GO0038147, q-value 1.73 × 10^{-5}), CXCL12-activated CXCR4 signaling pathway (GO0038160, q-value 1.73 × 10^{-5}), activation of phospholipase A2 activity by calcium-mediated signaling (GO0043006, q-value 1.73 × 10^{-5}), regulation of astrocyte activation (GO0061888, q-value 1.73 × 10^{-5}), positive regulation of protein kinase C activity (GO1900020, q-value 2.06 × 10^{-5}), neutrophil apoptotic process (GO0001781, q-value 2.06 × 10^{-5}), and positive regulation of apoptotic DNA fragmentation (GO1902512, q-value 2.27 × 10^{-5}).

5. Common Dysregulated miRNAs in AD, PD, and ALS

In the previous sections, we reported the altered expression of specific miRNA molecules in nervous tissue and fluids of patients with AD, PD, and ALS. Although each of these NDs has its own unique clinical aspects, they share common pathological features and etiopathogenetic mechanisms such as inflammation or apoptosis. Identification of commonly dysregulated miRNAs may provide useful insights into the implicated molecular pathways thus unrevealing novel potential drug targets.

Using the lists of commonly dysregulated miRNAs in human post-mortem nervous tissues and circulating fluids of AD, PD, and ALS patients (Tables 1–3), we identified 7 commonly dysregulated miRNAs (miR-9, miR-124, miR-218, miR-132, miR-133b, miR-338, miR-146a) (Figure 1). In particular, altered expression of miR-124 and miR-218 was reported in all the three NDs (Figure 1a). MiR-133b and miR-338 were dysregulated in PD and ALS, miR-132 in both PD and AD, while miR-9 and miR-146a in AD and ALS (Figure 1a). The regulatory interaction network among these overlapping miRNAs and their corresponding disease-associated targets shows a high level of interconnectedness, with miR-124 as the most interconnected node (hub) in the network and commonly dysregulated miRNA for the three NDs pathologies (Figure 2). This suggests the possibility to target a single miRNA and affect multiple pathogenic pathways.
In the previous sections, we reported the altered expression of specific miRNA downstream factors [263] (Tables 1–3, Figure 1). Specifically, in AD miR-124 modulates BACE1 [58,60] and APP [59] and tau phosphorylation levels through PTPN1 signaling [62], and its decrease was detected in the CSF of patients with the early stage of PD [136] (Table 2). In particular, aberrant expression of miR-124 in DNs leads to mitochondrial damage and cell death by targeting many key components of the AMPK/mTOR, NF-κB, and p25/CDK5 pathways, including p62/p38, STAT3, KPNB1, and Calpains 1–2 [107,136,153,158,159,162,164,264–266] (Table 2, Figure 2). In addition, miR-124 was also dysregulated in PD [158,164,264] and ALS [159,162] (Figure 1a). Reduced plasma miR-124 levels support its potential utility as a diagnostic biomarker in AD, supporting its role as a potential diagnostic biomarker in AD [43] (Table 1, Figure 2).

### Table 1: Dysregulated miRNAs in AD, PD, and ALS

| Disease | Total | Element |
|---------|-------|---------|
| AD - PD - ALS | 2 | miR-124, miR-218 |
| AD - PD | 1 | miR-132 |
| AD - ALS | 2 | miR-9, miR-146a |
| PD - ALS | 2 | miR-133b, miR-338 |

**Figure 1.** Dysregulated miRNAs in AD, PD, and ALS. List of commonly dysregulated miRNAs (a) and Venn diagram (b) of dysregulated miRNAs in the three NDs (Tables 1–3).

**Figure 2.** Interaction network of dysregulated miRNAs and their targets. The network was constructed using miRNet [260] and the miRNAs identified in this review as dysregulated in AD, PD, and ALS as an input list together with their disease-associated targets shown in Tables 1–3. Network visualization was obtained using the Cytoscape tool [261]. The most interconnected node (hub) is represented by miR-124 with a degree of connection of 36, while a degree of connection of 16 has been calculated for miR-218 which is also common to the three NDs pathologies. The blue diamond icons represent the dysregulated miRNAs, while ellipses represent target genes and are colored based on their disease association (yellow = PD; purple = ALS; light blue = AD).
In the next sections, we will describe these commonly dysregulated miRNAs and review their potential role and main targets.

5.1. Dysregulated miRNAs in AD, PD, and ALS

Several studies reported dysregulation of miR-124 in AD, PD, and ALS [225,262] (Tables 1–3). This represents one of the most abundant miRNAs in CNS and plays an important role in neuronal survival, autophagy, mitochondrial dysfunction, synapse morphology, oxidative damage, and neuroinflammation by modulating the activity of downstream factors [263] (Tables 1–3, Figure 1). Specifically, in AD miR-124 modulates both Aβ production by targeting BACE1 [58,60] APP [59] and tau phosphorylation levels through PTPN1 signaling [62], and its decrease was detected in the CSF of patients with AD, supporting its role as a potential diagnostic biomarker in AD [43] (Table 1, Figure 2). Reduced plasma miR-124 levels support its potential utility as a diagnostic biomarker in the early stage of PD [136] (Table 2). In particular, aberrant expression of miR-124 in DNs leads to mitochondrial damage and cell death by targeting many key components of AMPK/mTOR, NF-κB, and p25/CDK5 pathways, including p62/p38, STAT3, KPNB1, and Calpains 1–2 [107,136,153,158,162,164,264–266] (Table 2, Figure 2). In addition, miR-124 interacts with the modulator of BCL2-interacting mediator of cell death (Bim), whose suppression leads to reduction of Bax translocation to mitochondria and lysosomes, attenuating apoptosis and autophagosome accumulation [154] (Table 2, Figure 2). In ALS, miR-124 exerts a neuroprotective role in transgenic mice, by targeting Sox2 and Sox9, which encode two important regulators of neuronal and glial differentiation (Table 3, Figure 2) [223,225]. Differential expression of this miRNA can also be detected in both the spinal cord and leukocytes of sALS patients (Table 3) [222,227,228].

In addition to PD, AD, and ALS (Tables 1–3, Figure 1), miR-218, has been associated with neuropsychiatric disorders and other NDs [135,249,267,268]. In AD it is considered a potential peripheral biomarker [95] and was shown to regulate learning and memory in a mice AD model [94] and to affect the homeostasis between phosphorylated and dephosphorylated tau proteins [93] (Table 1, Figure 2). In PD models, miR-218 plays a role in modulating the NF-κB inflammatory signaling pathway, by influencing the activity of three importins, KPNB1, KPNA3, and KPNA4 [107], and interacts with the PD related gene PRKN [269], leading to mitochondrial dysfunction through the autophagic pathway [188] (Table 2, Figure 2). In addition, altered levels of miR-218 were found in brain regions and blood of PD patients [145] and were also associated with therapeutic brain stimulation [134,135] (Table 2). Dysregulation of miR-218 was also observed in ALS patients and animal models [212,229,248,251] (Table 3). A direct target of miR-218 in MNs is the voltage-gated potassium channel Kv10.1, whose upregulation was associated with an abnormal neuronal activity and excitability of MNs [249] (Table 3, Figure 2). It also targets EAAT2 (encoded by SLC1A2), an astrocytic glutamate excitatory amino acid transporter, that carries glutamate back into the cell after neurotransmission [248] and, when mutated, leads to impairment of glutamate levels, promoting post-synaptic neuronal cell death [270] (Table 3, Figure 2).

5.2. Dysregulated miRNAs in AD and PD

MiR-132 has been linked to several neurophysiological processes such as neuronal differentiation, migration and maturation, synaptic transmission, plasticity, and neuroprotection [271,272]. In particular, it represents one of the most-studied miRNAs in AD and, together with its downstream molecular targets (HDAC3, ITPKB, p250GAP, HNRNP, PTBP2, and SIRT1), is involved in the regulation of two AD pathological hallmarks: tau and Aβ [72–78] (Table 1, Figure 2). Dysregulated expression levels of this miRNA were found in the brain and CSF of AD patients and correlated with disease progression, supporting its use as an early biomarker (Table 1) [43]. MiR-132 was also proposed as a good candidate for monitoring PD progression as well as response to various therapeutic approaches [125,143,152] (Table 2). Upregulation of this miRNA was associated with
neuroinflammation, microglial activation, and DNs neurodegeneration [117,148] (Table 2, Figure 2).

5.3. Dysregulated miRNAs in AD and ALS

Among miRNAs differentially expressed in brain tissues and fluids of AD and ALS patients, miR-9 is a brain-specific miRNA that has demonstrated great potential as a biomarker (Tables 1 and 3, Figure 1). Its levels were reduced in the blood of LOAD patients [42] and correlated with disease severity [43] as was ell response to treatment in primary neurons (Table 1). In particular, the synapse-enriched miR-9 [40] regulates different AD-related genes (BACE1, CREB, OPTN, and CAMKK2) influencing Aβ production and autophagy [34,38–40], together with other targets related to neurotrophic proteins [41,273] (Table 1, Figure 2). MiR-9 plays an important role in regulating MNs development and its differential expression in ALS leukocytes supports its role as a diagnostic biomarker [218–220] (Table 3). Since it is known to interact with the 3′-UTRs of NEFL and PRPH and Pak4, its dysregulation may affect cell-cell junctions and axonal transport, leading to MN degeneration [17,218,220,274] (Table 3, Figure 2). Similar pathogenic mechanisms may follow the dysregulation of the NF-κB-sensitive miR-146a, implicated in the formation of pathological neurofilamentous aggregates [215,216,229], neuroinflammation, and immune response [55,65,85–88] (Tables 1 and 3, Figure 1). Differential expression of this miRNA in plasma and CSF of AD and ALS patients [65,85] supports its role as a potential biomarker [242] (Tables 1 and 3).

5.4. Dysregulated miRNAs in PD and ALS

As anticipated, miR-133b and miR-338 are dysregulated in PD and ALS (Tables 2 and 3, Figure 1). In particular, circulating miR-133b levels are altered in the early stages of PD [120] (Table 2). MiR-133 influences the maturation, function, and apoptosis of DNs [105,275–278] and also regulates RhoA, a protein modulating α-Synuclein expression [178,279] (Table 2, Figure 2). Increased serum level of miR-133b in ALS may influence skeletal muscle development [203,280] and neuromuscular junction maintenance/reinnervation [230,231] and targets several ALS-related genes, such as CCL2, CD4, FAS, EIF2C4/AGOA and AQP1 [212] (Table 3, Figure 2).

In PD, miR-338 has been functionally linked to DNs survival and its decrease in plasma extracellular vesicles has been proposed as a potential diagnostic biomarker [139] (Table 2). In ALS, this miRNA was found differentially expressed in blood, CFS, serum, and spinal cord, and its use as an effective early biomarker has been considered [222,251,252,254,255] (Table 3). From a functional point of view, miR-338 modulates the expression of COXIV and ATP synthase [281], as well as the ALS-related genes ARHGEF28 (involved in the aggregation of low molecular weight neurofilaments) and VAPB (involved in protein misfolding and ER-associated aggregates) [282,283]. Moreover, ectopic expression of miR-338 mediated by FoxO3a may play a critical role in reducing cell survival by directly suppressing the expression of NRP1 [284] (Table 3, Figure 2).

6. ASOs-Based miRNA Therapies

The leading approach against inappropriate miRNA expression is based on ASOs. ASOs-therapies are used to directly modulate the expression of mRNAs or miRNAs. They are based on single-stranded oligonucleotides forming a complementary heteroduplex with the targeted mRNA, complementary double-stranded oligonucleotides miming endogenous miRNAs, or single-stranded that inhibit miRNAs [285]. These molecules can be used to mimic (agomir) or, more often, inhibit (antagomir) specific miRNAs [285], and simultaneously affect the expression of multiple proteins [13,286]. To allow adequate bio-distribution of therapeutic ASOs to the brain and circumvent the BBB, they can be directly delivered to the CSF (ICV or intrathecal) [20,285]. Taking advantage of their ability to regulate the expression of multiple genes, therapies involving miRNAs offer this peculiar opportunity to be used in different pathologies.
Although no miRNA-based ASOs have yet entered the clinical phase in AD, PD, or ALS, some miRNA-based therapies have been pre-clinically tested in vitro or in vivo, and showed promising results either in AD [13,285], PD [269,277], or ALS [205,287,288]. One of the most interesting examples is miR-124, which is dysregulated in all three pathologies (Figure 1). In AD, miR-124 mimic was used to regulate BACE1 and alleviate cell death induced by Aβ neurotoxicity [289], and reduce APP gene expression [59], while the use of a miR-124 antagonir resulted in the attenuation of tau phosphorylation and increased PTPN1 levels [62]. In MPTP-induced mouse models of PD, the use of a miR-124 mimic promotes neuronal proliferation and suppression of neuronal apoptosis via the Hedgehog signaling pathway [157]. The over-expression of miR-124 significantly reverses the loss of DNs and striatal DA, and reduces autophagosome accumulation and lysosomal depletion in MPP(+)-intoxicated SH-SY5Y cells [154]. Exogenous delivery of miR-124 attenuates microglia activation in SN and apoptotic cell death in midbrain DA of MPTP-treated mice in vivo [153,158]. In addition, polymeric nanoparticles (NPs) have been used to deliver miR-124 to specific regions of the brain [290,291]. Normalization of miR-124 level in ALS cellular models by using miR-124-targeting drugs attenuates inflammatory responses by inhibiting the NF-kB signaling pathway and preventing neuronal death [225,226].

Neuroprotective effects were obtained with antagonir inhibition of miR-218, a miRNA dysregulated in AD, PD, and ALS patients. In vivo ASO-mediated inhibition of miR-218 has anti-inflammatory, anti-apoptotic, and antioxidant effects in ALS model mice by attenuating the loss of a key glutamate transporter, the excitatory amino acid transporter Slc1a2 [248].

Among miRNAs dysregulated in AD and PD (Tables 1 and 3, Figure 1), miR-132 showed promising therapeutic properties in AD mouse models, where treatment with miR-132 mimics restores memory function [79] and reduces phosphorylation of tau and Aβ [72,73]. Similar therapeutic effects were also obtained by inhibiting miR-9 and miR-146a, two miRNAs that are frequently dysregulated in AD and ALS (Tables 1 and 2, Figure 1). Indeed, miR-9 antagonir rescues upregulation of BACE1 [38], and promotes cognition and autophagic clearance of Aβ [39] in AD mice. ASO-based miR-146a mimic improves behavioral and cognitive dysfunction while attenuating neuroinflammation, glial activation, Aβ deposition, and tau phosphorylation in mice hippocampus [88].

7. Conclusions

The recognition that inappropriate production of individual miRNAs may contribute to NDs has invigorated interest in these molecules and hope for new diagnostic methods and therapeutical approaches. While the pathogenic role of inappropriate miRNA expression is being characterized, different strategies to mimic or inhibit these miRNAs by ASOs have been effectively tested in pre-clinical models of NDs. Although delivery of these ASOs therapies to brain cells remains a key obstacle, the successful translation from in vitro and experimental animal studies into clinical practice may soon allow the development of effective drugs.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12050770/s1, Table S1. GOs enrichment for dysregulated miRNAs in AD human nervous tissues and circulating fluids. Table S2. GOs enrichment for dysregulated miRNAs in PD human nervous tissues and circulating fluids. Table S3. GOs enrichment for dysregulated miRNAs in ALS human nervous tissues and circulating fluids.

Author Contributions: Conceptualization, G.G. and S.C.; methodology, G.G. and S.C.; formal analysis, G.G., G.M. and V.L.C.; investigation, G.G., G.M., V.L.C. and M.G.; resources, F.L.C. and S.C.; data curation, G.G., G.M. and V.L.C.; writing—original draft preparation, G.G., G.M., V.L.C., M.G. and S.C.; writing—review and editing, F.L.C. and S.C.; visualization, G.M. and M.G.; supervision, G.G. and S.C.; funding acquisition, F.L.C. and S.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the supplemental material.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AD = Alzheimer’s disease; Add1 = Adducin 1; ADORA2A = Adenosine A2a Receptor; AGO4 = Argonate RISC Component 4; ALS = Amyotrophic Lateral Sclerosis; AMPK = AMP-activated protein kinase; ANXA5 = Annexin A5; APOE = Apolipoprotein E; APP = Amyloid Beta Precursor Protein; AQP1 = Aquaporin 1; ARHGEF28 = Rho guanine nucleotide exchange factor 28; ASOs = antisense oligonucleotides; ATG5 = ATP Synthase Membrane Subunit C Locus 1; Aβ = amyloid-beta; miRNA = microRNA; BACE1 = Beta-Secretase 1; Bax = BCL2 Associated X, Apoptosis Regulator; BBB = blood-brain barrier; Bim = Bcl-2-like 11; C1q3 = complement C1q like 3; C3 = Complement C3; CAMK2A = Calcium/Calmodulin Dependent Protein Kinase II Alpha; CCL2 = C-C Motif Chemokine Ligand 2; CDK5 = Cycloid dependent kinase 5; CDKN1B = Cyclin Dependent Kinase Inhibitor 1B; CDKN2A = Cyclin Dependent Kinase Inhibitor 2A; CEBPB = CCAAT Enhancer Binding Protein Beta; CEBPD = CCAAT Enhancer Binding Protein Delta; CFH = Complement Factor H; CHMP2B = Charged Multivesicular Body Protein 2B; cIris-7 = circular RNA 7; CN5s = central nervous system; CNV = copy number variation; COXIV = Cytochrome C Oxidase Subunit 4; CREB = cAMP Responsive Element Binding Protein 1; CSF = cerebrospinal fluid; DA = dopamine; DAPK1 = Death Associated Protein Kinase 1; KLF4 = Kruppel Like Factor 4; DJ-1 = Parkinson7 Parkinsonism associated deglycase; DN = Dopaminergic neurons; DUSP6 = Dual Specificity Phosphatase 6; EAAT2 = Excitatory amino acid transporter 2; EDN2 = Endothelin 2; EOAD = early-onset AD; ER = endoplasmic reticulum; ERK = Extracellular Signal-Regulated Kinase; fAD = familial AD; FAIM = Fas Apoptotic Inhibitory Molecule; fALS = familial ALS; Fas = Cell Surface Death Receptor; FMR1 = FMRP translational regulator 1; Foxo3a = Forkhead box 03; Foxp1 = Forkhead Box P1; Fus = Fused in Sarcoma; Gdnf = Glial cell derived neurotrophic factor; GF = growth factor; GO = Gene Ontology; HDAC3 = Histone Deacetylase 3; HGMA2 = high mobility group A2; HNRNPK = Heterogeneous Nuclear Ribonucleoprotein K; HOTAIR = HOX antisense intergenic RNA; IGFB1 = insulin-like growth factor 1; IL-1R = Interleukin 1 receptor; IL-1β = Interleukin 1 Beta; IL-6 = Interleukin 6; iPSC = induced pluripotent stem cells; IRAK-1 = Interleukin 1 Receptor Associated Kinase 1; IRAK-2 = Interleukin 1 Receptor Associated Kinase 2; IRS-1 = Insulin receptor substrate 1; ITPKB = Inositol-Trisphosphate 3-Kinase B; Kcnh1 = Potassium Voltage-Gated Channel Subfamily H Member 1; KIF5A = Kinesin Family Member 5A; KPN3 = Karyopherin Subunit Alpha 3; KPN4A = Karyopherin Subunit Alpha 4; KPNB1 = Karyopherin Subunit Beta 1; LASS1 = Lim And SH3 Protein 1; Lhx1 = Lim Homeobox 1; LncRNA = Long non-coding RNA; LOAD = late-onset AD; LRRK2 = Leucine Rich Repeat Kinase 2; MALAT1 = Metastasis Associated Lung Adenocarcinoma Transcript 1; MAPT = Microtubule Associated Protein Tau; Mcp1p1 = Monocyte Chemotactic Protein-Induced Protein 1; MECP2 = Methyl-CpG Binding Protein 2; MEF2 = Mitogen-activated protein kinase kinase kinase 5; MIAT = myocardial infarction-associated transcript; MN = motor neuron; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP = 1-methyl-4-phenylpyridinium; mTOR = Mechanistic Target Of Rapamycin Kinase; NDs = neurodegenerative diseases; NEAT1 = nuclear paraspeckle assembly transcript 1; PDE4B = Phosphodiesterase 4B; NEFL = Neurofilament Light Chain; NF-kB = nuclear factor kappa-light-chain-enhancer of activated B cells; NFTs = neurofibrillary tangles; NMJ = neuromuscular junction; NP = nanoparticle; NR2A = N-methyl-D-aspartate (NMDA) receptor 2A; FMRP = fragile X mental retardation protein; PPAR = peroxisome proliferator-activated receptor; Nrf2 = Nuclear factor erythroid 2-related factor 2; NRP1 = Neuronal 1; Nur1 = nuclear receptor related 1 protein; OPTN = Optineurin; p250GAP = p250 GTPase-activating protein; PAK4 = Serine/threonine-protein kinase; PARK2 = Parkin; PD = Parkinson’s disease; PI3K = Phosphatidylinositol 3-kinases; PIK3R2 = Phosphatidylinositol 3-kinase regulatory subunit beta; PINK1 = PTEN Induced Kinase 1; PIP2 = phosphoinositide biphosphate; Pits3 = Paired Like Homeodomain 3; PLK2 = Polo-like Kinase 2; PPP1CA = Protein Phosphatase 1 Cat-
References

1. Ross, C.A.; Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10, S10–S17. [CrossRef] [PubMed]

2. Thal, D.R.; Fändrich, M. Protein aggregation in Alzheimer’s disease: Aβ and τ and their potential roles in the pathogenesis of AD. Acta Neuropathol. 2015, 129, 163–165. [CrossRef]

3. Gundersen, V. Protein aggregation in Parkinson’s disease. Acta Neurol. Scand. 2010, 122, 82–87. [CrossRef] [PubMed]

4. Blokhuis, A.M.; Groen, E.J.N.; Koppers, M.; Van Den Berg, L.H.; Pasterkamp, R.J. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125, 777–794. [CrossRef] [PubMed]

5. Breijyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 2020, 25, 5789. [CrossRef] [PubMed]

6. Mhyre, T.R.; Boyd, J.T.; Hamill, R.W.; Maguire-Zeiss, K.A. Parkinson’s Disease. Subcell Biochem. 2012, 65, 389–455. [CrossRef]

7. Shatunov, A.; Al-Chalabi, A. The genetic architecture of ALS. Neurobiol. Dis. 2020, 147, 105156. [CrossRef]

8. Brotman, R.G.; Moreno-Escobar, M.C.; Joseph, J.; Pawar, G. Amyotrophic Lateral Sclerosis; StatPearls Publishing: Treasure Island, FL, USA, 2022.

9. Mullard, A. ALS antisense drug fails in phase III. Nat. Rev. Drug Discov. 2021, 20, 883–885. [CrossRef]

10. Reddy, A.P.; Ravichandran, J.; Carkaci-Salli, N. Neural regeneration therapies for Alzheimer’s and Parkinson’s disease-related disorders. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2019, 1866, 165506. [CrossRef]

11. Paul, S.; Vázquez, L.A.B.; Uribe, S.P.; Reyes-Pérez, P.R.; Sharma, A. Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders. Cells 2020, 9, 1698. [CrossRef]

12. Maia, M.A.; Sousa, E. BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease. Pharmaceuticals 2019, 12, 41. [CrossRef] [PubMed]

13. Walgrave, H.; Zhou, L.; De Strooper, B.; Salta, E. The promise of microRNA-based therapies in Alzheimer’s disease: Challenges and perspectives. Mol. Neurodegener. 2021, 16, 76. [CrossRef] [PubMed]

14. Sharma, S.; Lu, H.C. microRNAs in Neurodegeneration: Current Findings and Potential Impacts. J. Alzheimer’s Dis. Park. 2018, 5, 139–148. [CrossRef] [PubMed]

15. Brennan, S.; Keon, M.; Liu, B.; Su, Z.; Saksena, N.K. Panoramic Visualization of Circulating MicroRNAs Across Neurodegenerative Diseases in Humans. Mol. Neurobiol. 2019, 56, 7380–7407. [CrossRef]

16. Hussein, M.; Magdy, R. MicroRNAs in central nervous system disorders: Current advances in pathogenesis and treatment. Egypt. J. Neurol. Psychiatry Neurosurg. 2021, 57, 36. [CrossRef]

17. Liu, J.; Zhou, F.; Guan, Y.; Meng, F.; Zhao, Z.; Su, Q.; Bao, W.; Wang, X.; Zhao, J.; Huo, Z.; et al. The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis. Cells 2022, 11, 572. [CrossRef]
18. Gu, S.; Jin, L.; Zhang, F.; Sarnow, P.; Kay, M.A. Biological basis for restriction of microRNA targets to the 3′ untranslated region in mammalian mRNAs. Nat. Struct. Mol. Biol. 2009, 16, 144–150. [CrossRef]

19. Nagaraj, S.; Zoltowska, K.M.; Laskowska-Kaszub, K.; Wojda, U. microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res. Rev. 2018, 49, 125–143. [CrossRef]

20. Bennett, C.F.; Krainer, A.R.; Cleveland, D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019, 42, 385–406. [CrossRef]

21. Ehrenberg, A.J.; Khatun, A.; Coomans, E.; Betts, M.J.; Capraro, F.; Thijssen, E.H.; Senkevich, K.; Bharucha, T.; Jafarpour, M.; Young, P.N.; et al. Relevance of biomarkers across different neurodegenerative. Alzheimer’s Res. Ther. 2020, 12, 56. [CrossRef]

22. Stavljenic–Rukavina, A. Molecular Mechanisms in Alzheimer’s Disease. EJIFCC 2004, 15, 100–103. [PubMed]

23. Kempf, S.J.; Metaxas, A. Neurofibillary tangles in Alzheimer’s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen. Res. 2016, 11, 1579. [CrossRef] [PubMed]

24. Madadi, S.; Schwarzhanbich, H.; Saidijam, M.; Mahjub, R.; Soleimani, M. Potential microRNA-related targets in clearance pathways of amyloid-β: Novel therapeutic approach for the treatment of Alzheimer’s disease. Cell Biosci. 2019, 9, 91. [CrossRef] [PubMed]

25. Cogswell, J.; Ward, J.; Taylor, I.; Waters, M.; Shi, Y.; Cannon, B.; Kelner, K.; Kemppainen, J.; Brown, D.; Chen, C.; et al. Identification of miRNA Changes in Alzheimer’s disease. J. Alzheimers Dis. 2008, 14, 27–41. [CrossRef]

26. Puthiyedath, N.; Riverso, C.; Berretta, R.; Moscato, P. Identification of Differentially Expressed Genes through Integrated Study of Alzheimer’s Disease Affected Brain Regions. PLoS ONE 2016, 11, e0152342. [CrossRef]

27. Frutos, M.F.-D.; Galán-Chilet, I.; Goedeke, L.; Kim, B.; Pardo-Marqués, V.; Pérez-Garcia, A.; Herrero, J.I.; Fernández-Hernando, C.; Kim, J.; Ramirez, C.M. MicroRNA-7 Impairs Insulin Signaling and Regulates Aβ Levels through Posttranscriptional Regulation of the Insulin Receptor Substrate 2, Insulin, Insulin-Degrading Enzyme, and Liver X Receptor Pathway. Mol. Cell. Biol. 2019, 39, e017019. [CrossRef]

28. Wang, W-X.; Huang, Q.; Hu, Y.; Stromberg, A.J.; Nelson, P.T. Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: White matter versus gray matter. Acta Neuropathol. 2010, 121, 193–205. [CrossRef]

29. Nelson, P.T.; Wang, W-X.; Janse, S.A.; Thompson, K.L. MicroRNA expression patterns in human anterior cingulate and motor cortex: A study of dementia with Lewy bodies cases and controls. Brain Res. 2017, 1678, 374–383. [CrossRef]

30. Hara, N.; Kikuchi, M.; Miyashita, A.; Hatsuta, H.; Saito, Y.; Kasuga, K.; Murayama, S.; Ikeuchi, T.; Kuwano, R. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol. Commun. 2017, 5, 10. [CrossRef]

31. Shi, Z.; Chen, T.; Yao, Q.; Zheng, L.; Zhang, Z.; Wang, J.; Hu, Z.; Cui, H.; Han, Y.; Han, X.; et al. The circular RNA ciRS-7 promotes APP and BACE1 degradation in an NF-κB-dependent manner. FEMS J. 2017, 284, 1096–1109. [CrossRef]

32. Zhao, Y.; Alexandrov, P.N.; Jaber, V.; Lukin, W.J. Deficiency in the Ubiquitin Conjugating Enzyme UBE2A in Alzheimer’s Disease (AD) is Linked to Deficits in a Natural Circular microRNA-7 Sponge (circRNA; ciRS-7). Genes 2016, 7, 116. [CrossRef] [PubMed]

33. Leidinger, P.; Backes, C.; Deutscher, S.; Schmitt, K.; Mueller, S.C.; Frese, K.; Haas, J.; Ruprecht, K.; Paul, F.; Stähler, C.; et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013, 14, R78. [CrossRef] [PubMed]

34. Hébert, S.S.; Horré, K.; Nicolai, L.; Papadopoulou, A.S.; Mandemakers, W.; Silahtaroglu, A.N.; Kauppinen, S.; Delacourte, A.; De Strooper, B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase secretion. Proc. Natl. Acad. Sci. USA 2008, 105, 6415–6420. [CrossRef] [PubMed]

35. Lukin, W.J. Micro-RNA specification in fetal, adult and Alzheimer’s disease hippocampus. NeuroReport 2007, 18, 297–300. [CrossRef]

36. Sethi, P.; Lukin, W.J. Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimer’s disease temporal lobe neocortex. Neurosci. Lett. 2009, 459, 100–104. [CrossRef]

37. Ishikawa, M.; Aoyama, T.; Shibata, S.; Sone, T.; Miyoshi, H.; Watanabe, H.; Nakamura, M.; Morota, S.; Uchino, H.; Yoo, A.S.; et al. miRNA-Based Rapid Differentiation of Purified Neurons from hPSCs Advancetowards Quick Screening for Neuronal Disease Phenotypes In Vitro. Cells 2020, 9, 532. [CrossRef]

38. Xie, H.; Zhao, Y.; Zhou, Y.; Liu, L.; Liu, Y.; Wang, D.; Zhang, S.; Yang, M. MiR-9 Regulates the Expression of BACE1 in Dementia Induced by Chronic Brain Hypoperfusion in Rats. Cell. Physiol. Biochem. 2017, 42, 1213–1226. [CrossRef]

39. Chen, M.-L.; Hong, C.-G.; Yue, T.; Li, H.-M.; Duan, R.; Hu, W.-B.; Cao, J.; Wang, Z.-X.; Chen, C.-Y.; Hu, X.-K.; et al. Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer’s disease by enhancing autophagy. Theranostics 2020, 11, 2395–2409. [CrossRef]

40. Chang, F.; Zhang, L.-H.; Xu, W.-P.; Jing, P.; Zhan, P.-Y. microRNA-9 attenuates amyloid-β-induced synaptotoxicity by targeting calcium/calmodulin-dependent protein kinase enzyme. Mol. Med. Rep. 2014, 9, 1917–1922. [CrossRef]

41. Schonrock, N.; Humphreys, D.; Preiss, T.; Götz, J. Target Gene Repression Mediated by miRNAs miR-181c and miR-9-Both of Which Are Down-regulated by Amyloid-β. J. Mol. Neurosci. 2011, 46, 324–335. [CrossRef]

42. Souza, V.C.; Morais, J.G.S.; Henriques, A.D.; Machado-Silva, W.; Perez, D.V.; Brito, C.J.; Camargos, E.F.; Moraes, C.F.; Nobrega, O.T. Whole-Blood Levels of MicroRNA-9 Are Decreased in Patients with Late-Onset Alzheimer Disease. Am. J. Alzheimer’s Dis. Other Dementias. 2020, 35, 153331752091157. [CrossRef] [PubMed]

43. Burgos, K.; Malenica, I.; Metpally, R.; Courtright, A.; Rakela, B.; Beach, T.; Shill, H.; Adler, C.; Sabbagh, M.; Villa, S.; et al. Profiles of Extracellular microRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer’s and Parkinson’s Diseases Correlate with Disease Status and Features of Pathology. PLoS ONE 2014, 9, e94839. [CrossRef]
44. Riancho, J.; Vázquez-Higuera, J.L.; Pozueta, A.; Lage, C.; Kazimierzczak, M.; Bravo, M.; Calero, M.; Gonzalez, A.; Rodriguez, E.; Lleó, A.; et al. MicroRNA Profile in Patients with Alzheimer’s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. J. Alzheimer’s Dis. 2017, 57, 483–491. [CrossRef] [PubMed]

45. Müller, M.; Kuiperij, H.B.; Claassen, J.A.; Küsters, B.; Verbeek, M.M. MicroRNAs in Alzheimer’s disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 2014, 35, 152–158. [CrossRef] [PubMed]

46. Liu, W.; Liu, C.; Zhu, J.; Shu, P.; Yin, B.; Gong, Y.; Qiang, B.; Yuan, J.; Peng, X. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol. Aging 2012, 33, 522–534. [CrossRef] [PubMed]

47. Hébert, S.S.; Papadopoulou, A.S.; Smith, P.; Galas, M.-C.; Plant, E.; Silhaatrogolu, A.N.; Sergeant, N.; Buée, L.; De Strooper, B. Genetic ablation of Dent in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 2010, 19, 3959–3969. [CrossRef]

48. Lu, C.-C.; Morgan, T.E.; Finch, C.E.; Zhou, X.J. Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer’s Disease Cortex Reveals Altered miRNA Regulation. Mol. Neurobiol. 2016, 53, 2984–2999. [CrossRef]

49. Kiko, T.; Nakagawa, K.; Tsuduki, T.; Furukawa, K.; Arai, H.; Miyazawa, T. MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer’s Disease. J. Alzheimer’s Dis. 2014, 39, 253–259. [CrossRef]

50. Müller, M.; Jäkel, L.; Bruinsma, I.B.; Claassen, J.A.; Kuiperij, B.; Verbeek, M.M. MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s disease. J. Alzheimer’s Dis. 2016, 55, 1223–1233. [CrossRef]

51. Nunez-Iglesias, J.; Liu, C.-C.; Morgan, T.E.; Finch, C.E.; Zhou, X.J. Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer’s Disease Cortex Reveals Altered miRNA Regulation. PLoS ONE 2015, 10, e8898. [CrossRef]

52. Gugliandolo, A.; Chircosta, L.; Boccardi, V.; Meocci, P.; Bramanti, P.; Mazzon, E. MicroRNAs Modulate the Pathogenesis of Alzheimer’s Disease: An In Silico Analysis in the Human Brain. Genes 2020, 11, 983. [CrossRef] [PubMed]

53. Klein, E.M.; Lioy, D.T.; Ma, L.; Impye, S.; Mandel, G.; Goodman, R.H. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat. Neurosci. 2007, 10, 1513–1514. [CrossRef] [PubMed]

54. Zhao, Y.; Bhattacharjee, S.; Jones, B.M.; Dua, P.; Alexandrov, P.N.; Hill, J.M.; Lukiw, W.J. Regulation of TREM2 expression by an FMRP-Associated MicroRNA miR-125b and miR-132. Stem Cell Rep. 2016, 7, 4299–4308. [CrossRef] [PubMed]

55. Galloway, N.; Slikker, W.; Sklvan, E.; Ito, K.; Yokota, Y.; Higashikubo, K.; Hikaru, S.; Sun, C.; Alcalay, R.N.; et al. MicroRNAs regulate FMRP in human neuronal precursor cells. EMBO J. 2010, 30, 195–205. [CrossRef]

56. S-P, H.; et al. MicroRNA Profile in Patients with Alzheimer’s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. J. Alzheimer’s Dis. 2017, 57, 483–491. [CrossRef] [PubMed]

57. Pogue, A.; Cui, J.; Li, Y.; Zhao, Y.; Culicchia, F.; Lukiw, W. Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci. Lett. 2010, 476, 18–22. [CrossRef] [PubMed]

58. Pomeshchik, Y.; Klementieva, O.; Gil, J.; Martinsson, I.; Hansen, M.G.; de Vries, T.; Sancho-Balsells, A.; Russ, K.; Savchenko, E.; Collin, A.; et al. Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem Cell Rep. 2020, 15, 256–273. [CrossRef] [PubMed]

59. Lu, W.; Liu, C.; Zhu, J.; Shu, P.; Yin, B.; Gong, Y.; Qiang, B.; Yuan, J.; Peng, X. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol. Aging 2012, 33, 522–534. [CrossRef] [PubMed]

60. Du, X.; Huo, X.; Yang, Z.; Hu, Z.; Botchway, B.O.; Jiang, Y.; Fang, M. miR-124 downregulates BACE1 and alters autophagy in APP/PS1 transgenic mice. Toxicol. Lett. 2017, 280, 195–205. [CrossRef]

61. Wang, X.; Liu, D.; Huang, H.-Z.; Wang, Z.-H.; Hou, T.-Y.; Yang, X.; Pang, P.; Wei, N.; Zhou, Y.; Dupras, M.-J.; et al. A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer’s Disease. J. Neurochem. 2020, 154, 441–457. [CrossRef] [PubMed]

62. Banzhaf-Strathmann, J.; Benito, E.; May, S.; Arzberger, T.; Tahirovic, S.; Kretzschmar, H.; Fischer, A.; Edbauer, D. Micro RNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J. 2014, 33, 1667–1680. [CrossRef] [PubMed]

63. Dangla-Valls, A.; Molinuevo, J.; Altirriba, J.; Sanchez-Valle, R.; Alcolea, D.; Fortea, J.; Rami, L.; Balasa, M.; Muñoz-Garcia, C.; Ezquerra, M.; et al. CSF microRNA Profiling in Alzheimer’s Disease: A Screening and Validation Study. Mol. Neurobiol. 2016, 54, 6647–6654. [CrossRef]
69. Lau, P.; Bossers, K.; Janky, R.; Salta, E.; Frigerio, C.S.; Barbash, S.; Rothman, R.; Sierksma, A.S.R.; Thathiah, A.; Greenberg, D.; et al. Alteration of the micro RNA network during the progression of Alzheimer’s disease. *EMBO Mol. Med.* 2013, 5, 1613–1634. [CrossRef]

70. Geng, L.; Zhang, T.; Liu, W.; Chen, Y. Inhibition of miR-128 Abates Aβ-Mediated Cytotoxicity by Targeting PPAR-γ via NF-κB Inactivation in Primary Mouse Cortical Neurons and Neuro2A Cells. *Yonsei Med. J.* 2018, 59, 1096–1106. [CrossRef]

71. Tiribuzi, R.; Crispoltoni, L.; Porcellati, S.; Di Lullo, M.; Florenzano, F.; Pirro, M.; Bagaglia, F.; Kawarai, T.; Zampolini, M.; Orlacchio, A.; et al. miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease. *Neurobiol. Aging* 2014, 35, 345–356. [CrossRef]

72. Smith, P.Y.; Hernandez-Rapp, J.; Jolivette, F.; Lecours, C.; Bisht, K.; Goupil, C.; Dorval, V.; Parsi, S.; Morin, F.; Planel, E.; et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. *Hum. Mol. Genet.* 2015, 24, 6721–6735. [CrossRef] [PubMed]

73. Salta, E.; Sierksma, A.; Vanden Eynden, E.; De Strooper, B. miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. *EMBO Mol. Med.* 2016, 8, 1005–1018. [CrossRef] [PubMed]

74. Hadar, A.; Milanesi, E.; Walczak, M.; Puzianowska-Kuznicka, M.; Kuznicki, J.; Squassina, A.; Niola, P.; Chillotti, C.; Attems, J.; Klein, M.E.; Varlamova, O.; Keller, D.M.; Yamamoto, T.; Goodman, R.H.; Impey, S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. *Proc. Natl. Acad. Sci. USA* 2005, 102, 16426–16431. [CrossRef] [PubMed]

75. Smith, P.Y.; Delay, C.; Girard, J.; Papon, M.-A.; Planel, E.; Sergeant, N.; Buee, L.; Hebert, S.S. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. *Hum. Mol. Genet.* 2011, 20, 4016–4024. [CrossRef]

76. Wei, Z.; Meng, X.; El Fatimy, R.; Sun, B.; Mai, D.; Zhang, J.; Arora, R.; Zeng, A.; Xu, P.; Qu, S.; et al. Environmental enrichment prevents Aβ oligomer-induced synaptic dysfunction through mirna-132 and hdac3 signaling pathways. *Neurobiol. Dis.* 2019, 134, 104617. [CrossRef]

77. Qu, J.; Xiong, X.; Huije, G.; Ren, J.; Yan, L.; Ma, L. MicroRNA-132-3p alleviates neuron apoptosis and impairments of learning and memory abilities in Alzheimer’s disease via inhibition of miR-132/212 expression in human primary neurons. *Cell Cycle* 2021, 20, 2309–2320. [CrossRef]

78. Walgrave, H.; Balusu, S.; Snoeck, S.; Eynend, E.V.; Craessaerts, K.; Thrupp, N.; Wolfs, L.; Horr, K.; Fourne, Y.; Ronisz, A.; et al. Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease. *Cell Stem Cell* 2021, 28, 1805–1821.e8. [CrossRef]

79. Guévermont, D.; Tsui, H.; Knight, R.; Fowler, C.J.; Masters, C.L.; Martins, R.N.; Abraham, W.C.; Tate, W.P.; Cutfield, N.J.; Williams, J.M. Plasma microRNA vary in association with the progression of Alzheimer’s disease. *Alzheimer’s Dement. Diagn. Assess. Dis. Monit.* 2022, 14, e12251. [CrossRef] [PubMed]

80. Zheng, K.; Hu, F.; Zhou, Y.; Zhang, J.; Zheng, J.; Lai, C.; Xiong, W.; Cui, K.; Hu, Y.-Z.; Han, Z.-T.; et al. miR-135a-5p mediates memory and synaptic impairments via the Rock2/Adducin1 signaling pathway in a mouse model of Alzheimer’s disease. *Nat. Commun.* 2021, 12, 1903. [CrossRef] [PubMed]

81. Liu, C.-G.; Wang, J.-L.; Liu, L.; Xue, L.-X.; Zhang, Y.-Q.; Wang, P.-C. MicroRNA-135a and -200b, potential Biomarkers for Alzheimer’s disease, regulate β secretase and amyloid precursor protein. *Brain Res. 2014, 1583, 55–64. [CrossRef] [PubMed]

82. Ko, C.-Y.; Chu, Y.-Y.; Narumiya, S.; Chi, J.-Y.; Furuyashiki, T.; Aoki, T.; Wang, S.-M.; Chang, W.-C.; Wang, J.-M. CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer’s disease. *Neurobiol. Aging* 2015, 36, 1356–1368. [CrossRef]

83. Yang, T.T.; Liu, C.G.; Gao, S.C.; Zhang, Y.; Wang, P.C. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer’s Disease Biomarkers. *Biomed. Environ. Sci. 2018, 31, 87–96. [CrossRef] [PubMed]

84. Lukiw, W.J.; Zhao, Y.; Cui, J.G. An NF-κB-sensitive Micro RNA-146a-mediated Inflammatory Circuit in Alzheimer Disease and in Stressed Human Brain Cells. *J. Biol. Chem.* 2008, 283, 31315–31322. [CrossRef] [PubMed]

85. Cui, J.G.; Li, Y.Y.; Zhao, Y.; Bhattacharjee, S.; Lukiw, W.J. Differential Regulation of Interleukin-1 Receptor-associated Kinase-1 (IRAK-1) and IRAK-2 by MicroRNA-146a and NF-κB in Stressed Human Astroglial Cells and in Alzheimer Disease. *J. Biol. Chem. 2010, 285, 38951–38960. [CrossRef]

86. Li, Y.Y.; Cui, J.G.; Dua, P.; Pogue, A.L.; Bhattacharjee, S.; Lukiw, W.J. Differential expression of miRNA-146a-regulated inflammatory genes in human primary neuronal and microglial cells. *Neurosci. Lett. 2011, 499, 109–113. [CrossRef]

87. Mai, H.; Fan, W.; Wang, Y.; Cai, Y.; Li, X.; Chen, F.; Chen, X.; Yang, J.; Tang, P.; Chen, H.; et al. Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model. *Mol. Ther.–Nucleic Acids 2019, 18, 681–695. [CrossRef]

88. Dong, H.; Li, J.; Huang, L.; Chen, X.; Li, D.; Wang, T.; Hu, C.; Xu, J.; Zhang, C.; Zen, K.; et al. Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease. *Dis. Markers 2015, 2015, 626569. [CrossRef]

89. Cao, J.; Huang, M.; Guo, L.; Zhu, L.; Hou, J.; Zhang, L.; Pero, A.; Ng, S.; El Gaamouch, F.; Elder, G.; et al. MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis. *Mol. Psychiatry 2020, 26, 4687–4701. [CrossRef]

90. Zhu, H.-C.; Wang, L.-M.; Wang, M.; Song, B.; Tan, S.; Teng, J.-F.; Duan, D.-X. MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1. *Brain Res. Bull.* 2012, 88, 596–601. [CrossRef]
116. Hoss, A.G.; Labadorf, A.; Beach, T.G.; Latourelle, J.C.; Myers, R.H. microRNA Profiles in Parkinson’s Disease Prefrontal Cortex. *Front. Aging Neurosci*. 2016, 8, 36. [CrossRef]

117. Gong, X.; Huang, M.; Chen, L. Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease. *Eurko Neuro 2022*, 9, ENEURO.0393-21.2021. [CrossRef]

118. Tatura, R.; Kraus, T.; Giese, A.; Arzberger, T.; Buchholz, M.; Höglinger, G.; Müller, U. Parkinson’s disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. *Park. Relat. Disord. 2016*, 33, 115–121. [CrossRef]

119. Tolosa, E.; Botta-Orfita, T.; Morató, X.; Calatayud, C.; Ferrer-Lorente, R.; Martí, M.-J.; Fernández, M.; Gaig, C.; Rayà, A.; Consiglio, A.; et al. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. *Neurol. Aging 2018*, 6, 283–291. [CrossRef]

120. Chen, Q.; Deng, N.; Lu, K.; Liao, Q.; Long, X.; Gou, D.; Bi, F.; Zhou, J. Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson’s disease. *Sci. Rep. 2022*, 11, 15268. [CrossRef]

121. Martins, M.; Rosa, A.; Guedes, L.C.; Fonseca, B.V.; Gotovac, K.; Violante, S.; Mestre, T.; Coelho, M.; Rosa, M.M.; Martin, E.R.; et al. Convergence of MicroRNA Expression Profile, α-Synuclein Interaction and GWAS in Parkinson’s Disease. *PLoS ONE 2011*, 6, e25443. [CrossRef]

122. Chi, J.; Xie, Q.; Jia, J.; Liu, X.; Sun, J.; Deng, Y.; Yi, L. Integrated Analysis and Identification of Novel Biomarkers in Parkinson’s Disease. *Front. Aging Neurosci. 2018*, 10, 178. [PubMed]

123. Zago, E.; Molin, A.D.; Dimitri, G.M.; Xumerle, L.; Pirazzini, C.; Bacalini, M.G.; Maturo, M.G.; Azevedo, T.; Spasov, S.; Gómez-Garré, P.; et al. Early downregulation of hsa-miR-144-3p in serum from drug-naive Parkinson’s disease patients. *Sci. Rep. 2022*, 12, 1330. [PubMed] [CrossRef]

124. Mo, M.; Xiao, Y.; Huang, S.; Chen, L.; Chen, X.; Zhang, L.; Luo, Q.; Li, S.; Yang, X.; Lin, X.; et al. MicroRNA expressing profiles in A33T mutant alpha-synuclein transgenic mice and Parkinsonian. *OncoTarget 2017*, 8, 15–28. [CrossRef] [PubMed]

125. Shu, Y.; Qian, J.; Wang, C. Aberrant expression of microRNA-132-3p and microRNA-146a-5p in Parkinson’s disease patients. *Open Life Sci. 2020*, 15, 647–653. [CrossRef]

126. Nonaka, W.; Takata, T.; Iwama, H.; Komatsubara, S.; Kobara, H.; Kamada, M.; Deguchi, K.; Touge, T.; Miyamoto, O.; Nakamura, T.; et al. A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy. *Mo. Med. Rep. 2022*, 25, 88. [CrossRef]

127. Sheinerman, K.S.; Toledo, J.; Tsivinsky, V.G.; Irwin, D.; Grossman, M.; Weintraub, D.; Hurtig, H.I.; Chen-Plotkin, A.; Wolk, D.A.; McCluskey, L.F.; et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimer’s Res. Ther. 2017*, 9, 89. [CrossRef]

128. Ding, H.; Huang, Z.; Chen, M.; Wang, C.; Chen, X.; Chen, J.; Zhang, J. Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. *Park. Relat. Disord. 2016*, 22, 68–73. [CrossRef]

129. Ma, W.; Li, Y.; Wang, C.; Xu, F.; Wang, M.; Liu, Y. Serum miR-221 serves as a biomarker for Parkinson’s disease. *J. Mol. Neurosci. 2016*, 61, 511–515. [CrossRef]

130. Ghit, A.; El Deeb, H. Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinson’s Disease. *J. Mol. Neur. 2022*, 72, 1133–1140. [CrossRef]

131. Zhang, X.; Yang, R.; Hu, B.-L.; Lu, P.; Zhou, L.-L.; He, Z.-Y.; Wu, H.-M.; Zhu, J.-H. Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease. *Front. Cell. Neur. 2017*, 11, 170. [CrossRef]

132. Manna, I.; Quattrone, A.; De Benedittis, S.; Vescio, B.; Iaccino, E.; Quattrone, A. Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: A pilot study. *Park. Relat. Disord. 2021*, 93, 77–84. [CrossRef]

133. He, S.; Huang, L.; Shao, C.; Nie, T.; Xia, L.; Cui, B.; Lu, F.; Zhu, L.; Chen, B.; Yang, Q. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease. *Transl. Neurodegener. 2021*, 10, 25. [CrossRef] [PubMed]

134. Soreq, L.; Solomonis, N.; Bronstein, M.; Greenberg, D.S.; Israel, Z.; Bergman, H.; Soreq, H. Small RNA sequencing-microarray analyses in Parkinson leucocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. *Front. Mol. Neurosci. 2013*, 6, 10. [CrossRef]

135. Da Silva, F.C.; Iop, R.D.R.; Vietta, G.G.; Kair, D.A.; Filho, P.G.; De Alvarenga, J.G.S.; Da Silva, R. microRNAs involved in Parkinson’s disease: A systematic review. *Mo. Med. Rep. 2016*, 14, 4015–4022. [CrossRef]

136. Angelopoulou, E.; Paudel, Y.N.; Piperi, C. miR-124 and Parkinson’s disease: A biomarker with therapeutic potential. *Pharmacol. Res. 2019*, 150, 104515. [PubMed]

137. Li, N.; Pan, X.; Zhang, J.; Ma, A.; Yang, S.; Ma, J.; Xie, A. Plasma levels of miR-137 and miR-124 are associated with Parkinson’s disease but not with Parkinson’s disease with depression. *Neur. Sci. 2017*, 38, 761–767. [CrossRef]

138. Ravanidis, S.; Bougea, A.; Papagiannakis, N.; Koros, C.; Simitsi, A.M.; Pachi, I.; Breza, M.; Stefanis, L.; Doxakis, E. Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients. *Ann. Clin. Transl. Neur. 2020*, 7, 1594–1607. [CrossRef]

139. Xie, S.; Niu, W.; Xu, F.; Wang, Y.; Hu, S.; Niu, C. Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson’s disease. *Int. J. Neursci. 2020*, 1–16. [CrossRef]

140. Marques, T.M.; Kuiperij, B.; Bruijnisa, I.B.; Van Rumund, A.; Aerts, M.B.; Esselink, R.A.J.; Bloem, B.R.; Verbeek, M.M. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy. *Mol. Neurobiol. 2017*, 54, 7736–7745. [CrossRef]
165. Cao, H.; Han, X.; Jia, Y.; Zhang, B. Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson’s disease via targeting miR-124-3p mediated FSTL1/NF-kB axis. Aging 2021, 13, 11455–11469. [CrossRef]

166. Liu, J.; Liu, D.; Zhao, B.; Jia, C.; Lv, Y.; Liao, J.; Li, K. Long non-coding RNA NEAT1 mediates MPTP/MPP+-induced apoptosis via regulating the mir-124/KLF4 axis in Parkinson’s disease. Open Life Sci. 2020, 15, 665–676. [CrossRef]

167. Han, Y.-P.; Liu, Z.-J.; Bao, H.-H.; Wang, Q.; Su, L.-L. miR-126-5p Targets Sp1 to Inhibit the Progression of Parkinson’s Disease. Eur. Neurol. 2022, 85, 235–244. [CrossRef]

168. Han, Y.-P.; Liu, Z.-J.; Bao, H.-H.; Wang, Q.; Su, L.-L. miR-126-5p Targets Sp1 to Inhibit the Progression of Parkinson’s Disease. J. Neurochem. Res. 2022, 74, 135465. [CrossRef]

169. Lin, Q.; Hou, S.; Dai, Y.; Jiang, N.; Lin, Y. LncRNA HOTAIR targets miR-126-5p to promote the progression of Parkinson’s disease through RAB3B. Biol. Chem. 2019, 400, 1217–1228. [CrossRef]

170. Lin, Q.; Hou, S.; Dai, Y.; Jiang, N.; Lin, Y. LncRNA HOTAIR targets miR-126-5p to promote the progression of Parkinson’s disease through RAB3B. Bioengineered 2021, 12, 665–676. [CrossRef] [PubMed]

171. Kim, W.; Noh, H.; Lee, Y.; Jeon, J.; Shin, S.; Shin, S.; Jeong, J.; Kim, H.-S.; Park, S.-Y.; Son, S.-H.; Koh, K. LncRNA NEAT1 regulates growth factor activities and vulnerability to toxic insult in neurons. Mol. Neurobiol. 2016, 53, 95–108. [CrossRef] [PubMed]

172. Schulz, J.; Takousis, P.; Wohlers, I.; Itua, I.O.; Dobricic, V.; Furuya, Y.; Rücker, G.; Binder, H.; Middleton, L.; Ioannidis, J.P.; Perneczky, R.; et al. Meta-analyses identify differentially expressed microRNAs in Parkinson’s disease. Aging 2019, 11, 9264–9279. [CrossRef]

173. Coccia, E.; Masanas, M.; López-Soriano, J.; Segura, M.F.; Comella, J.X.; Pérez-Garcia, M.J. FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b. Front. Cell Dev. Biol. 2020, 8, 584606. [CrossRef] [PubMed]

174. Niu, M.; Xu, R.; Wang, J.; Hou, B.; Xie, A. MiR-133b ameliorates axon degeneration induced by MPP+ via targeting RhoA. Neurosci. Lett. 2021, 740, 135465. [CrossRef]

175. Dong, L.G.; Lu, F.F.; Zu, J.; Zhang, W.-H.; Yang, X.X.; Xiao, Q.H.; Cui, C.C.; Xu, R.; et al. Up-regulated microRNA-218-5p regulates the differentiation of dopaminergic neurons by directly targeting Nurr1 expression. J. Cell. Physiol. 2021, 24, 11192–11198. [CrossRef]

176. Zhong, L.M.; Wang, M.-H.; Yang, H.-C.; Tian, T.; Sun, G.-F.; Ji, Y.-F.; Hu, W.-T.; Liu, X.; Wang, J.-P.; Lu, H. Dopaminergic neuron injury in Parkinson’s disease is mitigated by interfering lncRNA SNHG14 expression to regulate the miR-133b / α-synuclein pathway. Aging 2019, 11, 9264–9279. [CrossRef]

177. Zhou, S.; Zhang, D.; Guo, J.; Chen, Z.; Chen, Y.; Zhang, J. Long non-coding RNA NORAD functions as a microRNA-204-5p sponge to repress the progression of Parkinson’s disease in vitro by increasing the solute carrier family 5 member 3 expression. IUBMB Life 2020, 72, 2045–2055. [CrossRef]

178. Chiu, C.-C.; Yeh, T.-H.; Chen, R.-S.; Chen, H.-C.; Huang, Y.-Z.; Weng, Y.-H.; Cheng, Y.-C.; Liu, Y.-C.; Cheng, A.-J.; Lu, Y.-C.; et al. Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade. Front. Cell Neurosci. 2019, 13, 399. [CrossRef] [PubMed]

179. He, X.; Yang, L.; Huang, R.; Lin, L.; Shen, Y.; Cheng, L.; Jin, L.; Wang, S.; Zhu, R. Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist/miR-133b-3p/Ptx3 axis. J. Cell. Physiol. 2020, 235, 6032–6042. [CrossRef] [PubMed]

180. Li, K.; Zhang, J.; Ci, W.; Wang, A.L. MiR-144-3p and Its Target Gene LIF Regulate 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mitochondrial Dysfunction. Mol. Cells 2016, 39, 543–549. [CrossRef] [PubMed]

181. Zhou, S.; Zhang, D.; Guo, J.; Chen, Z.; Chen, Y.; Zhang, J. Long non-coding RNA NORAD functions as a microRNA-204-5p sponge to repress the progression of Parkinson’s disease in vitro by increasing the solute carrier family 5 member 3 expression. IUBMB Life 2020, 72, 2045–2055. [CrossRef]

182. Chiu, C.-C.; Yeh, T.-H.; Chen, R.-S.; Chen, H.-C.; Huang, Y.-Z.; Weng, Y.-H.; Cheng, Y.-C.; Liu, Y.-C.; Cheng, A.-J.; Lu, Y.-C.; et al. Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade. Front. Cell Neurosci. 2019, 13, 399. [CrossRef] [PubMed]

183. He, L.; Pan, X.; Wang, X.; Cao, Y.; Chen, P.; Du, C.; Huang, D. Rabec is a new target of miR-218 that can promote the progression of bladder cancer. Mol. Med. Rep. 2021, 24, 792. [CrossRef] [PubMed]

184. Ma, X.; Zhang, H.; Yin, H.; Geng, S.; Liu, Y.; Liu, C.; Zhao, J.; Liu, Y.; Wang, X.; Wang, Y. Up-regulated microRNA-218-5p ameliorates the damage of dopaminergic neurons in rats with Parkinson’s disease via suppression of LASP1. Brain Res. Bull. 2021, 166, 92–101. [CrossRef] [PubMed]

185. Di Rita, A.; Maiorino, T.; Bruci, K.; Volpicelli, E.; Bellenchi, G.C.; Strappazzon, F. miR-218 Inhibits Mitochondrial Clearance by Targeting PRKN E3 Ubiquitin Ligase. Int. J. Mol. Sci. 2020, 21, 355. [CrossRef] [PubMed]

186. Lang, Y.; Zhang, H.; Yu, H.; Li, L.; Liu, X.; Li, M. Long non-coding RNA myocardial infarction-associated transcript promotes 1-Methyl-4-phenylpyridinium ion-induced neuronal inflammation and oxidative stress in Parkinson’s disease through regulating microRNA-221-3p/ transforming growth factor / nuclear factor E2-related factor 2 axis. Bioengineered 2021, 13, 930–940. [CrossRef]
190. Lang, Y.; Li, Y.; Yu, H.; Lin, L.; Chen, X.; Wang, S.; Zhang, H. HOTAIR drives autophagy in midbrain dopaminergic neurons in the substantia nigra compacta in a mouse model of Parkinson’s disease by elevating NPTX2 via miR-221-3p binding. *Aging* **2020**, *12*, 7660–7678. [CrossRef]

191. Qian, C.; Ye, Y.; Mao, H.; Yao, L.; Sun, W.; Wang, B.; Zhang, H.; Xie, L.; Zhang, H.; Zhang, Y.; et al. Downregulated IncRNA-SNHG1 enhances autophagy and prevents cell death through the miR-221/222 /p27/mTOR pathway in Parkinson’s disease. *Exp. Cell Res.* **2019**, *384*, 111164. [CrossRef]

192. Oh, S.E.; Park, H.-J.; He, L.; Skibiel, C.; Junn, E.; Mouradian, M.M. The Parkinson’s disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. *Redox Biol.* **2018**, *19*, 62–73. [CrossRef] [PubMed]

193. Asci, R.; Vallefuoco, F.; Andolfo, I.; Bruno, M.; De Falco, L.; Iolascon, A. Transferrin receptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with MPP+ as Parkinson’s disease’s cellular model. *Neurosci. Res.* **2013**, *77*, 121–127. [CrossRef] [PubMed]

194. Zongaro, S.; Hukema, R.; D’Antoni, S.; Davidovic, L.; Barbry, P.; Catania, M.V.; Willemsen, R.; Mari, B.; Bardoni, B. The 3’ UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: Implications for the molecular pathology of FXTAS at the synapse. *Hum. Mol. Genet.* **2013**, *22*, 1971–1982. [CrossRef]

195. Sun, X.; Zhang, C.; Tao, H.; Yao, S.; Wu, X. LINC00943 acts as miR-338-3p sponge to promote MPP+-induced SK-N-SH cell injury by directly targeting SPI1 in Parkinson’s disease. *Brain Res.* **2022**, *1782*, 147814. [CrossRef]

196. Zhang, H.; Wang, Z.; Hu, K.; Liu, H. Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson’s disease model by targeting the miR-425-3p/TRAFL/NI-kB axis. *J. Biochem. Mol. Toxicol.* **2021**, *35*, e22867. [CrossRef]

197. Chiò, A.; Logroscino, G.; Traynor, B.; Collins, J.; Simeone, J.; Goldstein, L.; White, L. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. *Neuropediatrics* **2013**, *44*, 118–130. [CrossRef]

198. Jaiswal, M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. *Med. Res. Rev.* **2019**, *39*, 733–748. [CrossRef] [PubMed]

199. Zhang, Y.; Gu, J.; Sun, Q. Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis. *Cells* **2021**, *10*, 2247. [CrossRef]

200. Morgan, S.; Orrell, R.W. Pathogenesis of amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **2013**, *22*, 1971–1982. [CrossRef]

201. Butti, Z.; Patten, S.A. RNA Dysregulation in Amyotrophic Lateral Sclerosis. *Front. Genet.* **2019**, *9*, 712. [CrossRef]

202. Le Gall, L.; Anakor, E.; Connolly, O.; Vijayakumar, U.G.; Duddy, W.J.; Duguez, S. Molecular and Cellular Mechanisms Affected in ALS. *J. Pers. Med.* **2020**, *10*, 101. [CrossRef]

203. Emde, A.; Eitan, C.; Liou, L.; Libby, R.T.; Rivkin, N.; Magen, I.; Reichenstein, I.; Oppenheim, H.; Eilam, R.; Silvestroni, A.; et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS. *EMBO J.* **2015**, *34*, 2633–2651. [CrossRef]

204. Dardiotis, E.; Aloizou, A.-M.; Siokas, V.; Patrinos, G.P.; Deretzi, G.; Mitsias, P.; Aschner, M.; Tsatsakis, A. The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. *J. Mol. Neurosci.* **2018**, *66*, 617–628. [CrossRef] [PubMed]

205. Hamzei, H.; Suluyayla, R.; Brinkolf, C.; Janowski, S.J.; Hofestädt, R.; Allmer, J. Visualization and Analysis of miRNAs Implicated in Amyotrophic Lateral Sclerosis Within Gene Regulatory Pathways. *Ger. Med. Data Sci.* **2018**, *253*, 183–187. [CrossRef]

206. Butti, Z.; Patten, S.A. RNA Dysregulation in Amyotrophic Lateral Sclerosis. *Front. Genet.* **2019**, *9*, 712. [CrossRef]

207. Rinchetti, P.; Rizzuti, M.; Faravelli, I.; Corti, S. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. *Mol. Neurobiol.* **2017**, *55*, 2617–2630. [CrossRef]

208. Ling, S.-C.; Polymenidou, M.; Cleveland, D.W. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. *Acta Neuropathol. Commun.* **2014**, *3*, 127. [CrossRef] [PubMed]

209. Wakabayashi, K.; Mori, F.; Kakita, A.; Takahashi, H.; Utsumi, J.; Sasaki, H. Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. *Acta Neuropathol.* **2013**, *126*, 416–438. [CrossRef]

210. Rizzuti, M.; Filosa, G.; Melzi, V.; Calandriello, L.; Dioni, L.; Bollati, V.; Bresolin, N.; Comi, G.P.; Logroscino, G.; Traynor, B.; Collins, J.; Simeone, J.; Goldstein, L.; White, L. Global Epidemiology of Amyotrophic Lateral Sclerosis—Recent Advances and Therapeutic Challenges; Hegde, M.L., Ed.; IntechOpen: London, UK, 2019. [CrossRef]

211. Rinchetti, P.; Rizzuti, M.; Faravelli, I.; Corti, S. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. *Mol. Neurobiol.* **2017**, *55*, 2617–2630. [CrossRef]

212. Ling, S.-C.; Polymenidou, M.; Cleveland, D.W. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. *Acta Neuropathol. Commun.* **2014**, *3*, 127. [CrossRef] [PubMed]

213. De Santis, R.; Santini, L.; Colantoni, A.; Peruzzi, G.; de Torris, V.; Alfano, V.; Bozzoni, I.; Rosa, A. FUS Mutant Human Motoneurons Display Altered Transcriprome and microRNA Pathways with Implications for ALS Pathogenesis. *Stem Cell Rep.* **2017**, *9*, 1450–1462. [CrossRef] [PubMed]

214. D’Erchia, A.M.; Gallo, A.; Manzari, C.; Raho, S.; Horner, D.S.; Chiara, M.; Valletti, A.; Aiello, I.; Mastroppasqua, F.; Ciaccia, L.; et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. *Sci. Rep.* **2017**, *7*, 10046. [CrossRef] [PubMed]

215. Campos-Melo, D.; Droppeleman, C.A.; He, Z.; Volkenning, K.; Strong, M.J. Altered microRNA expression profile in amyotrophic lateral sclerosis: A role in the regulation of NFL mRNA levels. *Mol. Brain* **2013**, *6*, 26. [CrossRef]
216. Campos-Melo, D.; Hawley, Z.C.E.; Strong, M.J. Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Mol. Brain 2018, 11, 43. [CrossRef] [PubMed]

217. Zhang, Z.; Almeida, S.; Lu, Y.; Nishimura, A.L.; Peng, L.; Sun, D.; Wu, B.; Karydas, A.M.; Tartaglia, M.C.; Fong, J.C.; et al. Downregulation of MicroRNA-9 in iPSC-Derived Neurons of FTD/ALS Patients with TDP-43 Mutations. PLoS ONE 2013, 8, e76055. [CrossRef]

218. Hawley, Z.C.; Campos-Melo, D.; Strong, M.J. MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS). Brain Res. 2019, 1706, 93–100. [CrossRef]

219. Otaegi, G.; Pollock, A.; Hong, J. Sun, T. MicroRNA miR-9 Modifies Motor Neuron Columns by a Tuning Regulation of FoxP1 Levels in Developing SpinalCORDs. J. Neurosci. 2011, 31, 809–818. [CrossRef]

220. Cong, C.; Liang, W.; Zhang, C.; Wang, Y.; Yang, Y.; Wang, X.; Wang, S.; Huo, D.; Wang, H.; Wang, D.; et al. PAK4 suppresses motor neuron degeneration in hSOD1 G93A-linked amyotrophic lateral sclerosis cell and rat models. Cell Prolif. 2021, 54, e13003. [CrossRef]

221. Dobrowolny, G.; Martone, J.; Lepore, E.; Casola, I.; Petrucci, A.; Inghilleri, M.; Morlando, M.; Colantoni, A.; Scicchitano, B.M.; Calvo, A.; et al. A longitudinal study defined circulating miRNAs as reliable biomarkers for disease prognosis and progression in ALS patients. Cell Death Discov. 2021, 7, 4. [CrossRef]

222. Vrabec, K.; Boštjančič, E.; Koritnik, B.; Leonardis, L.; Grošelj, L.D.; Zidar, J.; Rogelj, B.; Glavač, D.; Ravnik-Glavač, M. Differential Expression of Several miRNAs and the Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients. Front. Mol. Neurosci. 2018, 11, 106. [CrossRef]

223. Zhou, F.; Zhang, C.; Guan, Y.; Chen, Y.; Lu, Q.; Jie, L.; Gao, H.; Du, H.; Zhang, H.; Liu, Y.; et al. Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: Altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. J. Neurochem. 2018, 145, 51–67. [CrossRef] [PubMed]

224. Han, D.; Dong, X.; Zheng, D.; Nao, J. MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders. Front. Pharmacol. 2020, 10, 1555. [CrossRef] [PubMed]

225. Vrabec, K.; Boštjančič, E.; Koritnik, B.; Leonardis, L.; Grošelj, L.D.; Zidar, J.; Rogelj, B.; Glavač, D.; Ravnik-Glavač, M. Differential Expression of Several miRNAs and the Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients. Front. Mol. Neurosci. 2018, 11, 106. [CrossRef]

226. Raheja, R.; Regev, K.; Healy, B.C.; Mazzola, M.A.; Beynon, V.; Von Glehn, F.; Paul, A.; Diaz-Cruz, C.; Gholipour, T.; Glanz, B.I.; et al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Neurobiol. Aging 2021, 93, 106. [CrossRef] [PubMed]

227. Dobrowolny, G.; Martone, J.; Lepore, E.; Casola, I.; Petrucci, A.; Inghilleri, M.; Morlando, M.; Colantoni, A.; Scicchitano, B.M.; Calvo, A.; et al. A longitudinal study defined circulating miRNAs as reliable biomarkers for disease prognosis and progression in ALS patients. Cell Death Discov. 2021, 7, 4. [CrossRef] [PubMed]

228. Yardeni, T.; Fine, R.; Joshi, Y.; Gradus-Pery, T.; Kozer, N.; Reichenstein, I.; Yanowski, E.; Nevo, S.; Weiss-Tishler, H.; Eisenberg-Bord, P.; et al. MiR-142-3p Regulates BDNF Expression in Activated Rodent Microglia Through Its Target CAMK2A. Int. J. Mol. Sci. 2018, 19, 475. [CrossRef] [PubMed]

229. Gupta, N.; Jadhav, S.; Tan, K.-L.; Saw, G.; Mallilankaraman, K.B.; Dheen, S.T. miR-142-3p Regulates BDNF Expression in Activated Rodent Microglia Through Its Target CAMK2A. Front. Cell. Neurosci. 2020, 14, 132. [CrossRef]

230. Mandolesi, G.; De Vito, F.; Musella, A.; Gentile, A.; Bullitita, S.; Fresegna, D.; Sepman, H.; Di Sanza, C.; Haji, N.; Mori, F.; et al. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation. J. Neurosci. 2017, 37, 546–561. [CrossRef] [PubMed]

231. Han, D.; Dong, X.; Zheng, D.; Nao, J. MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders. Front. Pharmacol. 2020, 10, 1555. [CrossRef] [PubMed]

232. Calvo, A.; et al. A longitudinal study defined circulating miRNAs as reliable biomarkers for disease prognosis and progression in ALS patients. Cell Death Discov. 2021, 7, 4. [CrossRef] [PubMed]

233. Yardeni, T.; Fine, R.; Joshi, Y.; Gradus-Pery, T.; Kozer, N.; Reichenstein, I.; Yanowski, E.; Nevo, S.; Weiss-Tishler, H.; Eisenberg-Bord, P.; et al. MiR-142-3p Regulates BDNF Expression in Activated Rodent Microglia Through Its Target CAMK2A. Int. J. Mol. Sci. 2018, 19, 475. [CrossRef] [PubMed]

234. Mandolesi, G.; De Vito, F.; Musella, A.; Gentile, A.; Bullitita, S.; Fresegna, D.; Sepman, H.; Di Sanza, C.; Haji, N.; Mori, F.; et al. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation. J. Neurosci. 2017, 37, 546–561. [CrossRef] [PubMed]

235. Wu, D.-M.; Wen, X.; Han, X.-R.; Wang, S.; Wang, Y.-J.; Shen, M.; Fan, S.-H.; Zhuang, J.; Zhang, Z.-F.; Shan, Q.; et al. MiR-142-3p Enhances Cell Viability and Inhibits Apoptosis by Targeting CDKN1B and TIMP3 Following Sciatic Nerve Injury. Cell. Physiol. Biochem. 2018, 46, 2347–2357. [CrossRef] [PubMed]

236. Paladino, S.; Conte, A.; Caggiano, R.; Pierantoni, G.M.; Faraonio, R. Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs. Cell. Physiol. Biochem. 2018, 47, 1951–1976. [CrossRef] [PubMed]

237. Yardeni, T.; Fine, R.; Joshi, Y.; Gradus-Pery, T.; Kozer, N.; Reichenstein, I.; Yanowski, E.; Nevo, S.; Weiss-Tishler, H.; Eisenberg-Bord, P.; et al. MiR-142-3p Enhances Cell Viability and Inhibits Apoptosis by Targeting CDKN1B and TIMP3 Following Sciatic Nerve Injury. Cell. Physiol. Biochem. 2018, 46, 2347–2357. [CrossRef] [PubMed]

238. Mandolesi, G.; De Vito, F.; Musella, A.; Gentile, A.; Bullitita, S.; Fresegna, D.; Sepman, H.; Di Sanza, C.; Haji, N.; Mori, F.; et al. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation. J. Neurosci. 2017, 37, 546–561. [CrossRef] [PubMed]

239. Raman, R.; Allen, S.; Goodall, E.; Kramer, S.; Ponger, L.-L.; Heath, P.R.; Milo, M.; Hollinger, H.C.; Walsh, T.; Highley, R.; et al. Gene expression signatures in motor neuron disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. Neuropathol. Appl. Neurobiol. 2015, 41, 201–226. [CrossRef]
240. De Luna, N.; Turon-Sans, J.; Cortes-Vicente, E.; Carrasco-Rozas, A.; Illán-Gala, I.; Dols-Icardo, O.; Clarín-M, J.; Lleó, A.; Gallardo, E.; Ila, I.; et al. Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Sci. Rep. 2020, 10, 4308. [CrossRef]

241. Fan, W.; Liang, C.; Ou, M.; Zou, T.; Sun, F.; Zhou, H.; Cui, L. MicroRNA-146a is a Wide-Reaching Neuroinflammatory Regulator and Potential Treatment Target in Neurodegenerative Diseases. Front. Mol. Neurosci. 2020, 13, 90. [CrossRef]

242. Banack, S.A.; Dunlop, R.A.; Cox, P.A. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: Towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol. 2020, 10, 200116. [CrossRef]

243. Cardoso, A.L.; Guedes, J.R.; de Almeida, L.P.; de Lima, M.C.P. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2011, 135, 73–88. [CrossRef] [PubMed]

244. Louafi, F.; Martinez-Nunez, R.T.; Sanchez-Elsner, T. MicroRNA-155 Targets SMAD2 and Modulates the Response of Macrophages to Transforming Growth Factor-β. J. Biol. Chem. 2010, 285, 41328–41336. [CrossRef] [PubMed]

245. Rai, D.; Kim, S.-W.; McKeller, M.R.; Dahlia, P.L.M.; Aguilar, R.C.T. Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 3111–3116. [CrossRef] [PubMed]

246. Paez-Colasante, X.; Figueroa-Romero, C.; Sakowski, S.A.; Goutman, S.; Feldman, E. Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenetic era. Nat. Rev. Neurol. 2015, 11, 266–279. [CrossRef] [PubMed]

247. Butovsky, O.; Jedrychowski, M.P.; Cialic, R.; Krasemann, S.; Murugaiyan, G.; Fanek, Z.; Greco, D.J.; Wu, P.M.; Doykan, C.E.; Kiner, O.; et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 2015, 77, 75–99. [CrossRef]

248. Hoye, M.L.; Regan, M.R.; Jensen, L.A.; Lake, A.M.; Reddy, L.V.; Vidensky, S.; Richardson, J.-P.; Maragakis, N.J.; Rothstein, J.D.; Hoye, M.L.; Rivkin, N.; Olender, T.; Toth, B.; et al. Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci. Transl. Med. 2019, 11, eaav5264. [CrossRef]

249. Thiebes, K.P.; Nam, H.; Cambronne, X.; Shen, R.; Glasgow, S.M.; Cho, H.-H.; Kwon, J.-S.; Goodman, R.H.; Lee, J.W.; Lee, S.; et al. miR-218 is essential to establish motor neuron fate as a downstream effector of Isl1–Lhx3. Nat. Commun. 2015, 6, 7718. [CrossRef]

250. De Felice, B.; Manfioletto, F.; Fiorentino, G.; Annunziata, A.; Biffali, E.; Pannone, R.; Federico, A. Wide-Ranging Analysis of MicroRNA Profiles in Sporadic Amyotrophic Lateral Sclerosis Using Next-Generation Sequencing. Front. Genet. 2018, 9, 310. [CrossRef]

251. De Felice, B.; Guida, M.; Guida, M.; Coppola, C.; De Mieri, G.; Cotrufo, R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012, 508, 35–40. [CrossRef]

252. Aschner, A.; Kar, A.N.; Natera-Naranjo, O.; MacGibeny, M.A.; Gioio, A.E.; Kaplan, B.B. MicroRNA-335 regulates the axonal expression of multiple nuclear-encoded mitochondrial miRNAs encoding subunits of the oxidative phosphorylation machinery. Cell. Mol. Life Sci. 2012, 69, 4017–4027. [CrossRef] [PubMed]

253. De Felice, B.; Annunziata, A.; Fiorentino, G.; Sorica, M.; Biffali, E.; Coppola, C.; Cotrufo, R.; Bassetto, S.; et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 2014, 15, 423–435. [CrossRef]

254. De Felice, B.; Annunziata, A.; Fiorentino, G.; Sorica, M.; Biffali, E.; Coppola, C.; Cotrufo, R.; Bassetto, S.; et al. miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Front. Mol. Neurosci. 2020, 13, 77. [CrossRef] [PubMed]

255. Saucier, D.; Wajnberg, G.; Roy, J.; Beauregard, A.-P.; Chacko, S.; Crapoulet, N.; Ghosh, A.; Lewis, S.; Marrero, A.; et al. Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res. 2019, 1708, 100–108. [CrossRef] [PubMed]

256. Wang, P.; Hou, J.; Lin, L.; Wang, C.; Liu, X.; Li, M.; Ma, F.; Wang, Z.; Cao, X. Inducible microRNA-155 Feedback Promotes Type I IFN Signaling in Antiviral Innate Immunity by Targeting Suppressors of Cytokine Signaling 1. J. Immunol. 2010, 185, 6226–6233. [CrossRef] [PubMed]

257. Lu, L.-F.; Thai, T.-H.; Calado, D.; Chaudhry, A.; Kubo, M.; Tanaka, K.; Loeb, G.B.; Lee, H.; Yoshimura, A.; Rajewsky, K.; et al. Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein. Immunity 2009, 30, 80–91. [CrossRef]

258. Xie, C.; Wang, H.; Zhang, Y.; Wei, Y. Neuroprotective effects of miR-142-5p downregulation against isoflurane-induced neurological impairment. Diagn. Pathol. 2020, 15, 70. [CrossRef]

259. Wang, N.; Zhang, L.; Lu, Y.; Zhang, Z.; Wang, K.; Lv, J. Down-regulation of microRNA-142-5p attenuates oxygen-glucose deprivation and reoxygenation-induced neuron injury through up-regulating Nrf2/ARE signaling pathway. Biomed. Pharmacother. 2017, 89, 1187–1195. [CrossRef]

260. Chang, L.; Zhou, G.; Soufan, O.; Xia, J. miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020, 48, W244–W251. [CrossRef]

261. Shannan, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of Biomolecular Interaction Networks. Genome Res. 2003, 13, 2498–2504. [CrossRef]

262. Ghafari, S.; Shoorei, H.; Bahroudi, Z.; Abak, A.; Majidpour, J.; Taheri, M. An update on the role of miR-124 in the pathogenesis of human disorders. Biomed. Pharmacother. 2021, 135, 111198. [CrossRef]

263. Amini, J.; Bibak, B.; Afshar, A.R.; Sahelbkar, A. Evaluation role of miR-124 in neurodegenerative diseases: Literature review and in silico analysis. bioRxiv 2021. [CrossRef]
264. Sun, K.-H.; de Pablo, Y.; Vincent, F.; Shah, K. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. *J. Neurochem.* 2008, 107, 265–278. [CrossRef] [PubMed]

265. Vosler, P.S.; Brennan, C.S.; Chen, J. Calpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration. *Mol. Neurobiol.* 2008, 38, 78–100. [CrossRef] [PubMed]

266. Li, S.; Bi, G.; Han, S.; Huang, R. MicroRNAs Play a Role in Parkinson’s Disease by Regulating Microglia Function: From Pathogenetic Involvement to Therapeutic Potential. *Front. Mol. Neurosci.* 2022, 14, 358. [CrossRef]

267. Sadr, N.K.S.; Shafiei, M.; Galedhari, H.; Khirolah, A. The Effect of Sialic Acid on the Expression of miR-218, NF-kB, MMP-9, and TIMP-1. *Biochem. Genet.* 2020, 58, 883–900. [CrossRef]

268. Torres-Berrios, A.; Nouel, D.; Cuesta, S.; Parise, E.M.; Restrepo-Lozano, J.M.; Larochelle, P.; Nestler, E.J.; Flores, C. MiR-218: A molecular switch and potential biomarker of susceptibility to stress. *Mol. Psychiatry* 2020, 25, 951–964. [CrossRef]

269. Nies, Y.H.; Najib, N.H.M.; Lim, W.L.; Kamaruzzaman, M.A.; Yahaya, M.F.; Teoh, S.L. MicroRNA Dysregulation in Parkinson’s Disease: A Narrative Review. *Front. Neurosci.* 2021, 15, 660379. [CrossRef]

270. Rosenblum, L.T.; Trott, D. EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis. *Adv. Neurobiol.* 2017, 16, 117–136. [CrossRef]

271. Qian, Y.; Song, J.; Ouyang, Y.; Han, Q.; Chen, W.; Zhao, X.; Xie, Y.; Chen, Y.; Yuan, W.; Fan, C. Advances in Roles of miR-132 in the Nervous System. *Front. Pharmacol.* 2017, 8, 770. [CrossRef]

272. Zhang, M.; Bian, Z. Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. *Front. Neurosci.* 2021, 15, 617. [CrossRef]

273. Shaik, M.M.; Tamargo, I.A.; Abubakar, M.B.; Kamal, M.A.; Greig, N.H.; Gan, S.H. The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials. *Genes* 2018, 9, 174. [CrossRef] [PubMed]

274. Ishtiaq, M.; Campos-Melo, D.; Volkening, K.; Strong, M.J. Analysis of Novel NEFL mRNA Targeting microRNAs in Amyotrophic Lateral Sclerosis. *PLoS ONE* 2014, 9, e85653. [CrossRef] [PubMed]

275. Tsai, I.M.; Yu, D. MicroRNAs in common diseases and potential therapeutic applications. *Clin. Exp. Pharmacol. Physiol.* 2010, 37, 102–107. [CrossRef]

276. Hébert, S.S.; De Strooper, B. Molecular biology: miRNAs in neurodegeneration. *Science* 2007, 317, 1179–1180. [CrossRef] [PubMed]

277. Leggio, L.; Vivarelli, S.; L’Episcopo, F.; Tirolo, C.; Caniglia, S.; Testa, N.; Marchetti, B.; Iacito, N. microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. *Int. J. Mol. Sci.* 2017, 18, 2698. [CrossRef]

278. Yadav, R.; Ramaswamy, P.; Pal, P.K.; Christopher, R. Clinical application of circulating micro RNAs in parkinson’s disease: The challenges and opportunities as diagnostic biomarker. *Ann. Indian Acad. Neurol.* 2020, 23, 84–97. [CrossRef]

279. Recasens, A.; Perier, C.; Sue, C.M. Role of microRNAs in the Regulation of alpha-Synuclein Expression: A Systematic Review. *Front. Mol. Neurosci.* 2021, 9, 128. [CrossRef]

280. Malacarne, C.; Galbiati, M.; Giagnorio, E.; Cavalcante, P.; Salerno, F.; Andreetta, F.; Cagnoli, C.; Taiana, M.; Nizzardo, M.; Andreetta, F.; et al. Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. *Int. J. Mol. Sci.* 2021, 22, 5673. [CrossRef]

281. Garza, M.T.G. MicroRNAs in Amyotrophic Lateral Sclerosis. In *Update on Amyotrophic Lateral Sclerosis*; Sibat, H.F., de Fatima Ibañez Valdés, L., Eds.; IntechOpen: London, UK, 2016. [CrossRef]

282. Daneshafrooz, N.; Joghataei, M.T.; Heidizadeh, M.; Alavi, A.; Barati, M.; Panahi, B.; Teimourian, S.; Zamani, B. Identification of let-7f and miR-338 as plasma-based biomarkers for sporadic amyotrophic lateral sclerosis using meta-analysis and empirical validation. *Sci. Rep.* 2020, 10, 12372. [CrossRef] [PubMed]

283. Di Gregorio, S.E.; Volkening, K.; Strong, M.J.; Duennwald, M.L. Inclusion Formation and Toxicity of the ALS Protein RGNF and Its Association with the Microtubule Network. *Int. J. Mol. Sci.* 2020, 21, 5597. [CrossRef]

284. Song, Y.; Zeng, S.; Zheng, G.; Chen, D.; Li, P.; Yang, M.; Luo, K.; Yin, J.; Gu, Y.; Zhang, Z.; et al. FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis. *Oncogene* 2020, 40, 777–790. [CrossRef] [PubMed]

285. Grabowska-Pyrzewicz, W.; Want, A.; Leszek, J.; Wojda, U. Antisense oligonucleotides for Alzheimer’s disease therapy: From the mRNA to miRNA paradigm. *elBioMedicine* 2021, 74, 103691. [CrossRef] [PubMed]

286. Liu, S.; Fan, M.; Zheng, Q.; Hao, S.; Yang, L.; Xia, Q.; Qi, C.; Ge, J. MicroRNAs in Alzheimer’s disease: Potential diagnostic markers and therapeutic targets. *Biomed. Pharmacother.* 2022, 148, 112681. [CrossRef] [PubMed]

287. Peplow, P.V.; Martinez, B. MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches. *Neural Regen. Res.* 2022, 17, 728. [CrossRef] [PubMed]

288. Mathis, S.; Le Masson, G. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis. *Biomedicines* 2018, 6, 9. [CrossRef]

289. Fang, M.; Wang, J.; Zhang, X.; Geng, Y.; Hu, Z.; Rudd, J.A.; Ling, S.; Chen, W.; Han, S. The miR-124 regulates the expression of BACE1/β-secretase with cell death correlated in Alzheimer’s disease. *Toxicol. Lett.* 2012, 209, 94–105. [CrossRef]

290. Gan, L.; Li, Z.; Lv, Q.; Huang, W. Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson’s disease model. *Int. J. Pharm.* 2019, 567, 118449. [CrossRef]

291. Saraiva, C.; Paiva, J.M.; Santos, T.; Ferreira, L.; Bernardino, L. MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson’s disease. *J. Control. Release* 2016, 235, 291–305. [CrossRef]